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ABSTRACT 
Alzheimer’s disease (AD) is a progressive, mentally crippling, and eventually 
fatal form of dementia with growing prevalence in aging populations.   In 2009 it was 
estimated that 5.3 million Americans have AD, with 5.1 million older than age 65 and 
200,000 under 65. That accounts for 1 in 8 adults over 65. Furthermore, AD costs 
Americans 148 billion dollars in direct expenses, and is the leading cause of dementia 
and the 6th leading cause of death. Since improved medical care in general is increasing 
average life span and age is the primary risk factor for AD, there is need for basic science 
research into the causes of and potential pharmacological treatments for this debilitating 
neurodegenerative disease.  
Preconditioning refers to endogenous adaptive responses to mild insults that 
induce a tolerant state, such that preconditioned tissues become resistant to a normally 
lethal insult. Our laboratories have shown that subchronic moderate ethanol 
preconditioning (MEP, 20-30mM for ~6d) protects organotypic brain slice cultures from 
amyloid-beta (Aβ), the neurotoxic peptide most often associated with AD. It is possible 
that the mechanism of MEP neuroprotection from Aβ toxicity may further our 
understanding of recent epidemiological results demonstrating a reduced risk of AD 
dementia in older moderate alcohol consumers.  
Whether MEP causes events analogous to those triggered during/by ischemic and 
other types of neuroprotective preconditioning has been little studied. Therefore, the 
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objective of this project was to elucidate the possible “sensor” roles of certain cell surface 
receptors in MEP-mediated neuroprotection from Aβ in vitro. Specifically, Gαi protein-
coupled receptors and/or glutamatergic N-methyl-D-aspartate receptors (NMDAR) have 
been shown to be involved in other neuroprotective preconditioning mechanisms. I 
hypothesize that MEP mediates neuroprotection from Aβ by the sensor activity of 
one or more of these cell surface receptors. The experiments employed rat cerebellar 
mixed cultures that show dose-related neurotoxicity in response to Aβ challenge and 
robust neuroprotection by MEP.  
The results of these studies implicate NMDAR activation—but rule against 
adenosine A1 receptors or other Gαi/o protein-coupled receptors—in attaining the 
neuroprotected phenotype promoted by MEP. Whereas inhibition of adenosine A1 
receptors with the selective antagonist, DPCPX, or of Gαi/o protein-coupled receptors 
with pertussis toxin failed to block MEP neuroprotection, inhibition of NMDAR with 
either the selective antagonist, AP5, or open channel blocker, memantine, effectively 
blocked it. Support for these findings was further demonstrated by the ability of 
preconditioning with NMDA itself to neuroprotect from Aβ-insult directly.  
MEP was then shown to modulate NMDAR by increasing receptor subunit 
expression and enhancing synaptic receptor localization, ultimately triggering pathways 
favoring prosurvival and protection against the neurotoxic Aβ. Specifically, NMDAR 
subunits NR1, NR2B and NR2C were elevated by day 2 of MEP treatment and remained 
increased through day 6. MEP also increased post-synaptic scaffolding protein PSD-95 
and the phosphorylation of tyrosine 1472 of NR2B— both of which are documented 
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markers for synaptically-localized NMDAR complex. These findings agree well with a 
growing literature on the dichotomous role of synaptic and extra-synaptic NMDAR on 
neuronal survival vs. excitotoxicity, respectively.  
Furthermore, two non-receptor tyrosine kinases known to modulate NMDAR 
synaptic activity and localization, Src and Pyk2, were shown to be phospho-activated in 
the cerebellar cultures at a timepoint that correlated with the increases in PSD-95 and 
NR2B-pY1472, implicating them in the targeting of the NMDAR to the synapse. These 
findings are intriguing, since PSD-95 has been shown to target Pyk2 to the synapse and 
provide Src with molecular scaffolding. Src can then interact with multiple MAPK 
pathways. 
Seeking further evidence, deconvolution microscopy was employed in order to 
visualize NMDAR localization in the cultures. The results of these experiments, done in 
collaboration with Dr. Edward Campbell’s laboratory in the Department of Microbiology 
and Immunology LUMC, showed an increase in PSD-95 association with NR2 subunits 
at day 6 of MEP. These results are consistent with the role of synaptic NMDAR in 
engendering the neuroprotective phenotype, in contrast to extra-synaptic NMDAR.  
It has been recently reported that synaptic NMDAR activity enhances resistance 
of neurons from oxidative stress by upregulating the peroxiredoxin-thioredoxin 
antioxidant pathway (Papadia et al., 2008). In exploring whether or not peroxiredoxins 
were increased in association with augmented NMDAR activity in the MEP model, initial 
evidence indicated that cytosolic peroxiredoxin-2 is increased by day 6, but not earlier—
correlating with the appearance of statistically significant MEP neuroprotection. This 
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result suggests a previously unappreciated “effector” in preconditioning neuroprotection. 
Since Aβ is know to induce oxidative stress, this finding may partially explain why MEP 
reduces Aβ neurotoxicity.    
Summarizing, the results show that MEP acts through a sensor, NMDAR, to 
promote neuroprotection. They provide insights into the molecular mechanism by which 
a receptor once thought responsible for the neurotoxicity of AD pathophysiology actually 
is modulated in a prosurvival way to induce neuroprotection. Hopefully, future research 
based on these preconditioning mechanisms might lead to new avenues of therapy that 
might be useful in AD, age-related cognitive decline, and potentially even vascular 
dementia (stroke).  
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CHAPTER ONE 
INTRODUCTION AND OVERVIEW 
 
Alzheimer’s disease (AD) is the leading cause of dementia. In 2009 the 
Alzheimer’s Association annual AD facts and figures publication estimated 5.3 million 
Americans of all ages have AD with 5.1million older than age 65 and 200,000 under 65. 
That accounts for 1 in 8 adults over 65 or 13% and a new case every 70 seconds. 
Furthermore, AD costs Americans $148 billion in direct expenses and is the 6th leading 
cause of death. Additionally, during the period between 2000 and 2006 the reported 
causes of death from heart disease, prostate cancer and stroke were reduced by -11.5,  
-14.3 and -18.1%, respectively, whereas over the same period, the reported cause of death 
from AD increased by a striking 47.1%.  
The etiology of AD is complex and is confounded by a milieu of contributing risk 
factors, including cognitive decline associated with normal aging and environmental 
circumstances such as social engagement, intellectual stimulation, diet and exercise, as 
well as certain genetic predispositions. The most notable genetic risk factor is the 
apolipoprotein E ε4 (ApoE4) allele that is observed in nearly 40% of sporadic AD. In fact 
one report that studied 42 families with late onset AD found that with increasing copy 
number of the allele, the risk of AD increased from 20% to 90% and the mean age of 
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onset decreased from 84 to 68 (Corder et al., 1993). Furthermore, microarray studies have 
identified numerous genetic mutations associated with AD, many of which seem to have 
completely divergent functions. This perplexing aspect of the disease makes identifying 
drug targets extremely difficult.  
Two pathological hallmarks of AD are insoluble extracellular deposits of amyloid 
beta (Aβ) peptide, sometimes referred to as senile plaques, and twisted strands of hyper-
phosphorylated tau protein within neurons, called neurofibrillary tangles. While there is 
debate over the exact mechanisms involved in the progression of Alzheimer’s disease, it 
is clear that Aβ peptide fragments formed from the proteolytic processing of amyloid 
precursor protein (sequential actions of β- and γ-secretases) are directly neurotoxic in 
vivo and in vitro. The prevailing theory for the development of AD, the “Amyloid 
Hypothesis”, posits that Aβ peptide overproduction is the main cause of the disease.  
Furthermore, it has been suggested that soluble levels of Aβ in the brain, more so than 
amyloid plaque burden, correlate with cognitive deficits among AD patients (Terry et al., 
1991; Naslund et al., 2000). Finally, Aβ peptides target memory processes in vivo (Haass 
and Selkoe, 2007). 
Aside from acetylcholinesterase inhibitors, memantine is the only FDA-approved 
drug that has shown promise in delaying AD-related cognitive decline. Memantine at 
physiologically relevant concentrations is believed to act primarily on the N-methyl-D-
aspartate subclass of glutamate receptors (NMDAR) at extra-synaptic sites to reduce 
excitotoxicity (Leveille et al., 2008) while allowing normal function of synaptically 
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localized NMDARs. However, it has also been shown to have affinity for α7 subunit-
containing nicotinic acetylcholine receptors (Aracava et al., 2005) that are also implicated 
in AD (Snyder et al., 2005). Furthermore, although improving medical care is increasing 
average life span, and age is the primary risk factor for AD, investigation into 
mechanisms that prevent or delay it are of the utmost importance. 
 The beneficial effects of moderate ethanol consumption on cardiovascular health 
are today well recognized (Agarwal, 2002); however, less appreciated is the growing 
evidence that alcohol in moderation produces beneficial effects in the brain. Several lines 
of evidence now suggest that moderate, as opposed to heavy, alcohol consumption is 
associated with a decreased probability of dementia, including AD, later in life (Zuccala 
et al., 2001;Mukamal et al., 2003). One recent report from participants in the Ginkgo 
Evaluation of Memory Study found that, after controlling for demographics, smoking, co-
morbidities, depression, social activity, and baseline cognition, moderate alcohol intake 
(defined as 8-14 drinks/week) was associated with a 40% lower risk of dementia in 
participants with normal cognition at the start of the study. However, this same study 
revealed that participants with mild cognitive impairment at the start of the study who 
drank heavily (>14 drinks/week) had a higher rate of progression to dementia.  
Although two other studies found that moderate alcohol consumption decreased 
the risk of AD (ApoE4 negative), they only reached statistical significance when they 
analyzed wine intake as opposed to any form of alcohol (Orgogozo et al., 1997; 
Luchsinger et al., 2004). However, two more recent meta-analyses (a more powerful 
4 
 
 
 
statistical analysis) found beneficial effects of moderate drinking on the relative risk for 
Alzheimer’s disease regardless of the type of alcohol consumed (Peters et al., 2008; 
Anstey et al., 2009). Thus it appears that there might be some mechanism by which 
moderate drinking affords neuroprotection from the neurodegenerative effects of AD 
pathology. 
Preconditioning refers to endogenous adaptive responses to mild insults that 
induce a tolerant state, such that preconditioned tissues become resistant to a normally 
lethal insult. Examples of preconditioning initiators include brief ischemia, hypoxia and 
an array of chemicals that induce cellular tolerance via a “sensor-transducer-effector” 
mechanism (Dirnagl et al., 2003). Our laboratories have shown that subchronic moderate 
ethanol preconditioning (MEP, 20-30mM for ~6d) protects organotypic brain slice 
cultures from dementia-associated neurotoxins such as HIV-1 gp120 or amyloid beta 
(Aβ) (Collins et al., 2000; Belmadani et al., 2004). MEP neuroprotection from Aβ 
toxicity may relate mechanistically to the aforementioned epidemiological results 
showing a reduced risk of dementia in older moderate alcohol consumers. Assessing 
whether MEP causes events analogous to those triggered during/by ischemic and other 
types of preconditioning has been little studied and was the focus of this project. Gαi 
protein-coupled receptors and or N-methyl-D-aspartate sensitive glutamate receptors 
(NMDARs) have been implicated in neuroprotective preconditioning mechanisms. 
Therefore, the objective of this specific project was to elucidate their possible “sensor” 
roles in MEP-mediated neuroprotection from Aβ in vitro. I hypothesized that MEP 
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mediates neuroprotection from Aβ by the sensor activity of one or more of these cell 
surface receptors. Experiments employed a model system of cerebellar mixed cultures 
that show dose-related neurotoxicity in response to Aβ challenge and robust 
neuroprotection by MEP. Although the cerebellum is relatively resistant to amyloid 
peptides in vivo (Kim et al., 2003), cerebellar granule neurons have been shown to be 
vulnerable to Aβ in vitro (Allen et al., 1999). Additionally, Aβ 25-35 was employed as 
the toxic insult, which, although not physiological, has a neurotoxic mechanism 
apparently identical to the most neurotoxic form in vivo, Aβ 1-42 (Frozza et al., 2008). 
The results of these studies implicate NMDAR activation—but rule against 
adenosine A1 or other Gαi/o protein-coupled receptors—in attaining the neuroprotected 
phenotype due to MEP. In short, whereas inhibition of the adenosine A1 receptor with the 
selective antagonist DPCPX, or of Gαi/o protein-coupled receptors with pertussis toxin 
failed to block MEP neuroprotection, inhibition of NMDARs with either the selective 
antagonist, AP5, or open channel blocker, memantine, effectively blocked it. Support for 
these findings was further demonstrated by the ability of preconditioning with NMDA 
itself to neuroprotect from Aβ-insult directly.  
MEP was shown to act via at least one novel mechanism, in that it modulates 
NMDARs to increase subunit expression and enhance synaptic receptor localization, 
ultimately triggering pathways favoring protection against the neurotoxic Aβ. 
Specifically, MEP elevates NMDAR subunits NR1, NR2B and NR2C by day 2 of the 
treatment, elevations that persist through day 6. Importantly, MEP also increases post-
6 
 
 
 
synaptic scaffolding protein PSD-95 and phosphorylation of tyrosine 1472 of the 
NMDAR2B subunit; both are markers for synaptically localized NMDAR complex. 
Theses findings are in harmony with a growing literature on the dichotomous role of 
synaptic and extra-synaptic NMDARs on neuronal survival vs. excitotoxicity, 
respectively (Vanhoutte and Bading, 2003).  
Two non-receptor tyrosine kinases known to modulate NMDAR synaptic activity 
and localization, Src and Pyk2, were shown to be phospho-activated at a timepoint that 
correlated with the increases in PSD-95 and NR2B-pY1472 expression, implicating their 
role in the targeting of the NMDAR to the synapse. These particular results are extremely 
intriguing, since PSD-95 has been shown to target Pyk2 to the synapse and provide 
molecular scaffolding for Src (Bartos et al., 2010). Src can then interact with multiple 
MAPK pathways, lending support for the hypothesis that MEP enhances postsynaptic 
responses via formation of a “postsynaptic signalosome” (Collins et al., 2009). The exact 
nature of this interaction is not yet fully understood and is the focus of additional study.  
Deconvolution microscopy was employed in order to visualize NMDAR 
localization. The results of these experiments showed an increase in the association of 
PSD-95 with NR2 subunits at day 6 of the preconditioning paradigm. These results are 
entirely consistent with the requirement of synaptic NMDARs to engender the 
neuroprotective phenotype in contrast to extra-synaptic NMDARs.  
Recently, it was shown that synaptic NMDAR activity enhances resistance of 
neurons from oxidative stress by upregulating the peroxiredoxin-thioredoxin antioxidant 
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pathway (Papadia et al., 2008). Therefore I investigated whether the peroxiredoxins were 
increased by MEP. I found that indeed there is evidence that cytosolic peroxiredoxin-2 is 
increased by day 6 of MEP, but not earlier—correlating with the appearance of MEP 
neuroprotection. This identifies a previously unappreciated “effector” in preconditioning 
neuroprotection. Since Aβ is know to induce oxidative stress, this finding may partially 
explain why MEP reduces Aβ neurotoxicity.    
Summarizing, the results show that MEP acts through the NMDAR to engender 
neuroprotection and provides clarity on the molecular mechanism by which a receptor 
once thought responsible for the neurotoxicity of AD pathophysiology actually is 
modulated in a pro-survival way by MEP to induce neuroprotection. Hopefully, in 
continuing with this work, research may lead to new avenues of therapy within the 
spectrum of AD, age-related cognitive decline and potentially vascular dementia. The 
following background presents a selected discussion of a vast but pertinent literature and 
relevant data related to this project. 
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CHAPTER TWO 
REVIEW OF LITERATURE 
2.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive, mentally crippling and eventually fatal 
form of dementia with growing prevalence in aging populations. Early symptoms of AD 
include difficulty remembering names and recent events, apathy and depression. Over 
time, symptoms become more severe and include impaired judgment, disorientation, 
confusion, behavior changes, and trouble speaking, swallowing and walking in later 
stages. In the final stages of the disease people lose their ability to communicate, and to 
recognize loved ones and require constant medical attention. Symptoms result from 
massive synaptic degeneration that leads to neuronal death and shrinking of brain matter. 
Two pathological hallmarks of AD are insoluble deposits of Aβ peptide referred to as 
senile plaques and twisted strands of hyper-phosphorylated tau protein found within 
neurons called neurofibrillary tangles. Although it is currently unknown whether these 
histological markers accumulate as a result of disease progression or are themselves 
causative factors, amyloid peptides are directly neurotoxic in vivo and in vitro, and 
genetic manipulations that enhance accumulation of these pathological hallmarks account 
for the majority of animal models of the disease. Neurofibrillary tangles appear to be the 
result of Aβ pathology (Canevari et al., 2004).  
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AD is the leading cause of dementia. In 2009  it was estimated that 5.3 million 
Americans of all ages have AD, with 5.1 million older than age 65 and 200,000 under 65 
(derived from the Alzheimer’s Association 2009 “Facts and Figures”). That accounts for 
1 in 8 adults over 65 or 13%. Furthermore, AD costs Americans 148 billion dollars in 
direct expenses and is the 6th leading cause of death. During a period between 2000 and 
2006 the reported causes of death for heart disease, prostate cancer and stroke were 
reduced by -11.5, -14.3 and -18.1%, respectively, whereas over the same period the 
reported cause of death from AD increased by a striking 47.1% (2009).  
Although improving medical care in general is increasing average life span, since 
age is the primary risk factor for AD, clearly there is need for basic science research into 
the cause of and potential pharmacological treatment of this crippling neurodegenerative 
disease. This point is underscored by the failure of most pharmacological approaches that 
target the NMDAR to have beneficial outcomes. Because of the enormous socioeconomic 
burden and growing prevalence of AD, investigation into its cause and potential 
therapeutics is of great concern. 
 
2.2 Mechanisms of amyloid neurotoxicity 
The prevailing theory of the cause of AD is the “Amyloid Hypothesis” that posits 
that amyloid peptides and the dysregulation of their production are the cause of AD. The 
exact mechanism of Aβ neurotoxicity is complex and is thought to involve altered 
fluctuations in intracellular calcium (Ho et al., 2001) and excessive production of reactive 
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oxygen species (ROS) (Benzi and Moretti, 1995). While there is debate over the exact 
mechanisms involved in the progression of AD, it is clear that the peptide fragments 
formed from the proteolytic processing of amyloid precursor protein (sequential actions 
of β- and γ- secretases) are directly neurotoxic in vivo and in vitro. Correlations between 
the brain levels of these peptide products and the degree of cognitive impairment in AD 
have demonstrated that synaptic loss is the major anatomical correlate of cognitive 
decline in AD (Naslund et al., 2000).  
There is also evidence that in AD patients, living neurons show decreased 
synaptic content and transcripts of vesicle trafficking machinery, underscoring the fact 
that AD is a synaptopathy (Coleman and Yao, 2003). As such, postsynaptic density 
preparations from cingulate cortex and hippocampus of AD brains have an increased 
density of pro-caspase-3 and active caspase-3 when compared to controls (Louneva et al., 
2008). Soluble amyloid oligomers have been shown to target memory processes (Haass 
and Selkoe, 2007). For example, soluble amyloid oligomers rapidly impair plasticity of 
excitatory synaptic transmission in hippocampus (Hu et al., 2008) and facilitate 
NMDAR- and mGluR-dependent long-term depression (LTD) of electrical activity in 
hippocampal CA1 neurons (Li et al., 2009).  
However, there does seem to be an important physiological role for amyloid 
peptides in normal brain function (Pearson and Peers, 2006).  Plant and colleagues found 
that inhibiting the production of amyloid peptides in primary central neurons with 
secretase inhibitors or an antibody that binds Aβ resulted in a marked decrease in cell 
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viability, which was rescued by addition of Aβ 1-40 but not 1-42 or Aβ 25-35 (Plant et 
al., 2003). Furthermore, picomolar concentrations of a preparation containing monomeric 
and oligomeric Aβ enhanced hippocampal LTP and enhanced both reference and 
contextual fear memory in mice (Puzzo et al., 2008). Higher (nanomolar) concentrations 
had inhibitory effects. These effects were shown to be mediated by α7 nicotinic 
acetylcholine receptors. Therefore, it must be remembered that AD results from a 
dysregulation of normal physiological processes in the brain. 
 
2.3 Aβ and NMDAR 
The etiology of AD has long been thought to involve the NMDAR, which are 
important intermediaries in learning and memory, although the exact nature of this 
interaction is a matter of debate. Early hypotheses predicted an overactivation of 
NMDAR by Aβ in AD, but the data available demonstrate an inhibitory effect of amyloid 
peptides on NMDAR-dependent postsynaptic potentials and disruption of the 
postsynaptic density. Importantly, naturally secreted Aβ oligomers potently inhibit 
hippocampal LTP in vivo (Walsh et al., 2002). Long term potentiation (LTP) and long 
term depression (LTD) are cellular forms of memory that are activity-dependent and have 
opposing effects on postsynaptic strength. LTP, induced by way of high-frequency 
tetanic stimulus in vitro or by conditioned learning in vivo, enhances postsynaptic signals 
in hippocampus, whereas LTD induced chemically or otherwise depresses them. These 
effects on the excitability of neurons in response to different tonic stimuli are believed to 
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underlie memory consolidation and learning, since they can last for prolonged durations, 
and impairment of these effects by various stimuli impairs cognition in several animal 
models including AD. Although multiple forms of this phenomenon exist, NMDAR-
facilitated forms are believed to be fundamental to memory and learning (Lacor et al., 
2007).   In hippocampus, LTP increases the surface expression of NMDARs in a protein 
kinase C (PKC)- and tyrosine kinase-dependent manner (Grosshans et al., 2002). 
Furthermore, Aβ impairs NMDAR-dependent LTP but neither non-NMDAR dependent 
LTP nor the induction of LTD in dentate gyrus slice cultures (Wang et al., 2004b); these 
effects were attributed to inflammatory microglia-induced production of superoxide and 
nitric oxide. Interestingly, an elegant study by Shankar and colleagues found that amyloid 
oligomers induced progressive loss of hippocampal dendritic spines, and when applied 
acutely, decreased NMDAR-dependent calcium influx through synaptic spines in 
organotypic hippocampal slice cultures (Shankar et al., 2007). Total antagonism of 
NMDAR with 20µM 3-[(±)-2-carboxypiperazin-4-yl]-propyl-1-phosphonate (CPP) 
blocked this effect and partial blockade (200-400nM CPP) mimicked it. The researchers 
concluded that the partial inhibition of NMDARs by Aβ oligomers or partial 
pharmacological inhibition, pathways that favor LTD, were responsible for the decrease 
in spine density and were dependent on activity of the actin disassembling enzyme, 
cofilin, and the protein phosphatase, calcineurin (Shankar et al., 2007). 
Roselli and coworkers found that soluble Aβ(1-40) caused dose- and time-
dependent decreases in PSD-95 that were NMDAR- and calcium- dependent and were 
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inhibited by GABA receptor blocker bicuculline or a metabotropic II/III glutamate 
receptor antagonist, but were not AMPA receptor-dependent since 2,3-dihydroxy-6-nitro-
7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), an AMPA antagonist, failed to 
have an effect (Roselli et al., 2005). They further showed the decrease in PSD-95 to 
involve cdk5 and the proteasome pathway. However, an Aβ(1-42) preparation containing 
monomeric and oligomeric peptides bound to NMDAR-containing synapses and 
inhibited NMDAR function. The effect was not due to a direct NMDAR inhibition, since 
acute application of their preparation failed to alter NMDAR currents in hippocampal 
cultures or xenopus oocytes expressing recombinant NMDAR. Pre-incubation with this 
preparation decreased NMDAR subunit immunoreactive spines and surface expression of 
NR2B-containing NMDAR. Employing a transgenic model of AD, Dewachter and 
coworkers also showed that postsynaptic density preparations from APP[V717I] 
transgenic mice contained decreased concentrations of NR2B and PSD-95 (Dewachter et 
al., 2007).  
Others have found that application of Aβ cause endocytosis of NMDARs in 
cortical neurons and decreased NMDAR positive synaptic spines. This study showed a 
potent inhibitory effect of Aβ peptides on NMDA- evoked currents and, importantly, 
inhibition of NMDA signaling via CREB. These researchers also provide compelling 
evidence that the effects of Aβ on NMDAR surface expression were α-7 nicotinic 
acetylcholine receptor-dependent, protein phosphatase 2B (PP2B, also know as 
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calcineurin)- and striatal enriched protein phosphatase (STEP)-dependent, and correlated 
with decreased phosphorylation of NR2B-Y1472 (Snyder et al., 2005).  
Although the exact nature of the effect of Aβ on the NMDAR and its role in 
synaptic strength, architecture, and learning and memory processes remains to be fully 
elucidated, loss of functional NMDAR synapses is associated with behavioral and 
cognitive deficits in AD patients (Venkitaramani et al., 2007). 
 
2.4 Moderate ethanol and Alzheimer’s 
Although several reports indicate a beneficial effect of moderate-to-light ethanol 
consumption on the incidence of AD, two recent meta-analyses have helped to clarify this 
effect in humans. Anstey and colleagues analyzed data from 15 prospective studies 
including 14,646 participants with AD, vascular dementia (VaD) and any dementia and 
showed the relative risk (RR) of moderate drinkers to non-drinkers to be 0.72, 0.75 and 
0.74, respectively (Anstey et al., 2009). When more generally classified into “drinkers” 
or “non-drinkers”, RR became 0.66 for AD and 0.53 for any dementia, but no significant 
difference for any dementia. There was not enough data to determine the RR for VaD 
under these criteria. Heavy drinkers did not have an increased risk, but the authors’ state 
that this could be due to sampling bias. “…alcohol drinkers in late life have reduced risk 
of dementia. It is unclear whether this reflects selection effects in cohort studies 
commencing in late life, a protective effect of alcohol consumption throughout 
adulthood, or a specific benefit of alcohol in late life” (Anstey et al., 2009).  
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Additionally, a meta-analysis by Peters et al. (2008) evaluated the relationship 
between alcohol consumption and incident cognitive decline or dementia in the elderly. 
The inclusion criteria were longitudinal studies of subjects 65 or older, with primary 
outcomes of incident dementia/cognitive decline. They identified 23 studies (20 
epidemiological cohort and three retrospective matched case-controls nested in a cohort) 
and found statistically reduced RRs of dementia (0.63) and AD (0.57) among drinkers 
when compared to abstainers, but not for VaD (0.82) or cognitive decline (0.89). 
“However, studies varied with differing lengths of follow up, measurement of alcohol 
intake, inclusion of true abstainers and assessment of potential confounders. Because of 
the heterogeneity in the data these findings should be interpreted with caution. However, 
there is some evidence to suggest that limited alcohol in earlier adult life may be 
protective against incident dementia later” (Peters et al., 2008). Thus, it appears that there 
is a significant degree of neuroprotection from AD and general dementia observed in 
moderate-to-light drinking adults. It is possible that this may reflect to some degree the 
MEP neuroprotection from Aβ observed in vitro. 
 
2.5 Preconditioning 
Conserved among organisms is an inherent ability to adapt to stress or 
environmental change. Preconditioning in general refers these adaptive responses to mild 
stressful stimuli that induce a tolerant state, such that preconditioned tissues are rendered 
resistant to a much stronger and normally lethal insult. There are two classical phases of 
16 
 
 
 
preconditioning, the  acute phase that is short-lived (typically 1-3h) and independent of 
protein synthesis (not blocked by cycloheximide) (Perez-Pinzon et al., 1997; Perez-
Pinzon and Born, 1999), and the delayed phase that is long-lasting (typically from 1-7 
days) and dependent on new protein synthesis (Barone et al., 1998). The first description 
of cardiac preconditioning in mammals described this early phase and was published in 
1985 by Murry and colleagues. They demonstrated that brief periods of ischemia induced 
tolerance to a later, more prolonged normally lethal episode of ischemia in dog heart 
(Murry et al., 1986). Since then, examples have grown to include not only ischemia, but a 
number of traumas and a wide array of chemicals that induce tolerance, as well as 
examples of cross-tolerance, remote preconditioning and postconditioning. Furthermore, 
preconditioning has been demonstrated in multiple organ systems, including heart, brain 
(Kitagawa et al., 1990), lung (Luo et al., 1997) and kidney (Islam et al., 1997). However, 
although a great body of literature has promoted a better understanding of the 
mechanisms involved, many aspects have yet to be fully elucidated. One recent report 
that is highly relevant to our work demonstrated that moderate to low (single bolus, 42-46 
mg/kg peak blood level) ethanol preconditioning is capable of inducing delayed (24h) 
cross-tolerance that is protective against global cerebral ischemia in gerbils (Wang et al., 
2007) via a mechanism involving NADPH oxidase-derived ROS. Interestingly, many of 
the underlying mechanisms of preconditioning-mediated protection are homologous 
throughout various tissue types and stimuli. Dirnagl et al. (2003) provides a conceptual 
framework that separated the various signaling mechanisms common in brain 
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preconditioning into “sensors” (events that signal to the cell that there is a stressor 
present), “transducers” (molecules such as kinases and transcription factors that transduce 
information from the environment to the nucleus), and “effectors” (that are the physical 
entities such as heat shock proteins and anti-apoptotic enzymes that account for the 
protected state) (Dirnagl et al., 2003). However, although this model of brain 
preconditioning provides a logical paradigm to investigate specific signaling events 
within preconditioning models, it should be recognized that many of these signaling 
pathways and intermediaries overlap spatially and temporally. What follows is a review 
of some of the key research in the area of preconditioning mechanisms of heart and brain. 
 
2.6 NMDA receptors in preconditioning 
In the brain, NMDAR activation is commonly associated with excitotoxicity. 
However, several models of preconditioning have demonstrated the role of NMDARs in 
mediating neuroprotection (Kato et al., 1992; Miao et al., 2005; Jiang et al., 2005; Wang 
et al., 2006; Xifro et al., 2006). Exposure of murine cortical cell cultures to 
preconditioning doses of glutamate or NMDA has been shown to be neuroprotective 
(Grabb and Choi, 1999). Similarly, exposure of cerebellar granule cell cultures to sub-
excitotoxic concentrations of NMDA has been shown to cause neuroprotection 
attributable to release of brain-derived neurotrophic factor (BDNF) acting on receptor 
tyrosine kinase B (TrkB) (Marini et al., 1998). Both NMDA and BDNF exposure result 
in activation of the transcription factor nuclear factor κB (NF-κB), and inhibition of NF-
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κB with an oligonucleotide decoy reversed neuroprotection from glutamate-mediated 
excitotoxicity (Wu et al., 2005). Neuroprotection in this model correlates with expression 
of anti-apoptotic bcl-2. NMDA receptor activation is also associated with mitogen-
activated protein kinase (MAPK) activity. In a rat model of ischemic preconditioning 
(IPC), inhibition of NMDAR signaling blocked ERK5 activation, an effect that reversed 
hippocampal CA1 neuroprotection (Wang et al., 2006). That same study showed 
inhibition of ERK5 with antisense oligonucleotide also prevented neuroprotection, 
demonstrating dependence on NMDAR-mediated ERK5 activation for IPC. In that 
regard, transient calcium influx into hippocampal neurons causes calcium/calmodulin 
kinase (CaMK)-dependent Ras/MAPK activation (Wu et al., 2001). This work exposed a 
biphasic activation of cyclic AMP response element binding protein (CREB). The early 
phase was dependent on CaMK and the latter phase on MAPK. In another study, NMDA 
was capable of protecting cerebellar granule cell cultures from potassium deprivation 
(Xifro et al., 2006). Protection in this model correlated with inhibition of pro-apoptotic c-
jun N-terminal kinase (JNK) and expression of anti-apoptotic bcl-2. 
 
2.7 Gαi protein-coupled receptors in preconditioning 
Much of what is known about the early cell signaling events in preconditioning 
result from research on ischemic preconditioning of heart. Advances made in the field of 
ischemic preconditioning have paved the way for insight into several other forms of 
preconditioning. One such advance was identification of the involvement of G-protein 
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coupled receptors in preconditioning. Activation of Gαi protein-coupled receptors is one 
of the earliest signals in the induction of ischemic preconditioning-mediated protection.  
Adenosine is an established mediator of ischemic preconditioning in the heart and 
in the brain, and the adenosine A1 receptor is expressed in several tissues including brain 
(Heurteaux et al., 1995). In heart, adenosine (Liu et al., 1991), bradykinin (Goto et al., 
1995), and opioids (Bell et al., 2000) signal through Gαi protein-coupled receptors and 
are capable of stimulating preconditioning-mediated protection. The 7-transmembrane 
domain receptors are coupled to heterotrimeric G proteins having Gα and Gβγ subunits. 
Upon ligand binding, the Gα subunit exchanges GDP for GTP and dissociates. Both Gα 
and Gβγ subunits are biologically active, and cessation of signaling occurs by the 
inherent GTPase activity of Gα, which upon hydrolysis of GTP, re-assembles with Gβγ. 
Gαi signaling inhibits adenylyl cyclase and may both activate K+ channels and inhibit 
Ca2+ channels. Gβγ is coupled to PI3 kinase (PI3K) (Naga Prasad et al., 2000), which is 
believed to be a critical mediator of protection in several forms of preconditioning.  
2.8 Kinase signaling in preconditioning 
PI3K phosphorylates membrane phospholipids, leading to recruitment and 
activation of phosphatidylinositol-specific phospholipase C (PI-PLC) and hydrolysis of 
membrane phosphatidylinositol 4,5-bisphosphate. This results in release of inositol 
trisphosphate (IP3) and diacylglycerol (DAG) that in turn activate isoforms of protein 
kinase C (PKC) (Nishizuka, 1992). Activation of at least one PKC isoform is thought to 
be a ubiquitous transducer of preconditioning stimuli, and the phosphoinositide products, 
20 
 
 
 
DAG and IP3, are common activators of PKC isoforms. In hippocampal slice cultures, 
εPKC has been shown to be required for both NMDA- and ischemia-mediated 
preconditioning (Raval et al., 2003). εPKC and δPKC, members of the novel class of 
PKC isozymes, have been identified as controlling survival/apoptosis signaling in 
preconditioning. These two enzymes have been shown to have opposing effects, with 
εPKC favoring protection (Speechly-Dick et al., 1994) and δPKC initiating apoptosis 
(Bright et al., 2004).  
PI3K can also mediate protection by way of protein kinase B (PKB), also known 
as AKT (Chan et al., 1999). PKB may be a potent modulator of protection, since it is 
capable of phosphorylating several mediators of preconditioning. In heart, acetylcholine, 
which induces protection through G protein-coupled muscarinic receptors, has been 
shown to transactivate the epidermal growth factor (EGF) receptor, leading to activation 
of PKB (Krieg et al., 2002). This activation was blocked by both the Src inhibitor 4-
Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrzolo[3,4-d]pyrimidine (PP2) and the EGF 
receptor inhibitor N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine (AG-1478). 
The transactivation of EGF by G protein-coupled receptors may be mediated through 
Gβγ, since sequestration of the subunit with C-terminus of β-adrenergic receptor kinase 
(ßARKct, an inhibitor of the Gβγ subunit of G protein-coupled receptors) inhibited 
transactivation (Pierce et al., 2001). PKB phosphorylates and activates endothelial nitric 
oxide synthase (eNOS) and 70-kDa ribosomal protein S6 kinase (p70S6K), both of which 
are implicated in preconditioning. Also, PKB phospho-inhibits GSK3β and BAD, two 
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proteins that have apoptotic functions. GSK3β is intimately involved with MPT pore 
formation, and its inhibition has been hypothesized to be the “master switch” upon which 
preconditioning signals culminate (Juhaszova et al., 2004). Proapoptotic BAD, which 
also favors MPT formation, is sequestered by 14-3-3 protein upon phosphorylation 
(Scheid and Woodgett, 2001). 
In the heart, extracellular signal-regulated kinase (ERK) is another postulated 
transducer of preconditioning-mediated protection (Fryer et al., 2001). It has been 
demonstrated that ischemic preconditioning results in PKC-dependent phosphorylation of 
ERK (Baines et al., 2002). Also, delayed preconditioning mediated by activation of 
mitochondrial KATP is abrogated by inhibition of ERK with MEK1/2 inhibitor, PD 98059. 
Indeed, ERK activation may be due to mitoKATP dependent release of ROS (Gross et al., 
2003). A role of ERK activation in receptor-mediated endosomal trafficking and survival 
signaling has also been proposed, since blocking endosomal trafficking, inhibition of 
PI3K and sequestration of Gβγ all inhibit ERK phosphorylation and IPC-mediated 
protection (Tong et al., 2003). 
 
2.9 PKC and redox signaling in preconditioning 
The translocation and activation of PKC isozymes is very sensitive to redox 
signaling, since antioxidants inhibit PKC-mediated responses (Gopalakrishna and Jaken, 
2000). Structural data support the direct activation of PKC by redox signaling. The N-
terminal domain of PKC contains a cysteine-rich zinc finger motif susceptible to 
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oxidation by H2O2. When oxidized, the enzyme loses its auto-inhibitory effect and 
becomes active (Gopalakrishna and Anderson, 1989). Conversely, the C-terminal domain 
contains cysteines that are targets of antioxidants (Gopalakrishna and Anderson, 1991). 
Modifications of this type decrease PKC activity. It is therefore possible that through its 
redox properties, PKC couples mitochondrial ROS generation to gene transcription in the 
preconditioning pathway. 
 
2.10 ROS in preconditioning 
Based on emerging evidence, particularly concerning the role of mitochondria, 
ROS might function as cellular second messengers in preconditioning signaling. This is 
supported by the observation that antioxidants such as N-acetylcysteine (a glutathione 
precursor) (Das and Maulik, 2003) and dimethyl thiourea (a hydroxyl radical scavenger) 
(Das et al., 1999) abolish the delayed protective effect of ischemic preconditioning in 
heart. PI3K (Qin and Chock, 2003) and MAPKs (Pain et al., 2000) have established roles 
in preconditioning and both are activated by ROS. Certain redox-sensitive transcription 
factors have been shown to be critical in ischemic preconditioning. If nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) activity is inhibited with SN 50 
peptide (an inhibitor of NFκB nuclear translocation), ischemic preconditioning protection 
of heart is abolished (Das et al., 1999). Furthermore, NFκB is translocated into the 
nucleus during ischemic preconditioning, and this action is blocked by antioxidants (Das 
et al., 1999). This activity may be mediated by redox-sensitive tyrosine kinases 
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(Gopalakrishna and Anderson, 1989). NFκB is responsible for control of several 
apoptosis-related genes, including anti-apoptotic bcl-2 and pro-apoptotic genes bax and 
p53 (Bromme and Holtz, 1996). Thus, redox signaling in this way is capable of 
regulating apoptosis. 
 
2.11 Mitochondria and preconditioning 
The mitochondria represent a central mediator of apoptosis, but they are now 
being recognized as intermediaries of cytoprotection as well. Although the precise roles 
of mitochondria in preconditioning-mediated protection are topics of debate, it is 
generally accepted that preconditioning-initiated protection involves both the 
mitochondrial ATP-dependent potassium (mitoKATP) channel and inhibition of 
mitochondrial permeability transition (MPT) pore formation. Many of the known cellular 
mediators of protection have also been shown to activate the mitoKATP channel, including 
nitric oxide (NO) (Sasaki et al., 2000), PKC (Sato et al., 1998) and ROS (Zhang et al., 
2001). Activation of the mitoKATP channel leads to depolarization of the mitochondrial 
inner-membrane potential (Ψm), which attenuates mitochondrial Ca2+ accumulation 
during ischemia/reperfusion (Liu et al., 1998). This effect has been correlated with a 
decrease in MPT pore formation (Murata et al., 2001).  
In another study using isolated mitochondria, both diazoxide (mitoKATP channel 
opener) and myristic acid (PKC activator) were protective from anoxic injury (Korge et 
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al., 2002), and these effects were abolished by 5-hydroxydecanoic acid (5-HD), an 
inhibitor of the mitoKATP channel. Protection in this study correlated with depolarization 
of Ψm and decrease in mitochondrial Ca2+ accumulation. Furthermore, there was 
inhibition of MPT formation upon reoxygenation, indicating a potential correlation 
between mitoKATP channel activation and inhibition of mitochondrial-driven apoptosis. 
Activation of the mitoKATP channel and subsequent depolarization of Ψm have also been 
demonstrated to result in generation of superoxide anion in a preconditioning model of 
angiotensin II-mediated protection (Kimura et al., 2005). This was demonstrated 
elsewhere, with the addition of diazoxide (Pain et al. 2000). In this last study, protection 
afforded by diazoxide was blocked by inhibition of mitochondrial ROS with antioxidants. 
These findings are compelling when considering the ability of ROS to affect diverse 
mediators of preconditioning-mediated protection. 
 
2.12 CREB and preconditioning 
CREB, a transcription factor affecting multiple genes in response to intracellular 
calcium, has been shown to mediate both the development of hypoxia/ischemia-induced 
brain damage, and for mechanisms of brain repair (Walton et al., 1996). In addition, 
CREB-dependent gene expression is involved in learning and memory, neuronal 
differentiation and survival (Carlezon et al., 2005). Considering the critical role of CREB 
in neuronal homeostasis, it is not surprising that it is a central intermediary of brain 
preconditioning. For example, CREB is required for ischemic preconditioning-induced 
25 
 
 
 
ischemic tolerance in gerbil hippocampal CA1 neurons (Hara et al., 2003). Phospho-
activated CREB is also increased for days following transient ischemia in rat brain 
dentate granule cells (Hu et al., 1999).  
What is more, CREB signaling has been shown to upregulate anti-apoptotic bcl-2 
following oxygen-glucose deprivation preconditioning in vitro and ischemic 
preconditioning in rats (Meller et al., 2005). Neuroprotection in this study was blocked by 
CREB oligonucleotide decoy, which also blocked Bcl-2 expression. Also, inhibitors of 
protein kinase A, CaMK and mitogen-activated protein kinase/extracellular signal-
regulated kinase (MEK) inhibited preconditioning protection. In another study, increases 
in intracellular calcium through NMDA receptors or L-type calcium channels caused 
enhanced CREB phosphorylation, an effect mediated by mitochondrial calcium-
dependent superoxide signaling (Hongpaisan et al., 2003); however, another study found 
NADPH-oxidase and not mitochondria to be responsible for NMDAR-dependent ROS in 
hippocampus (Brennan et al., 2009). 
 
2.13 Synaptic vs. extra-synaptic NMDAR and CREB 
Interestingly, it is not merely the activity but importantly the localization of the 
NMDAR that appears important for mediating its neuroprotective vs. excitotoxic effects. 
This is because of an emerging literature on the opposing roles of synaptic vs. extra-
synaptic NMDARs in neuronal survival and death pathways (Vanhoutte and Bading, 
2003). Hardingham and coworkers demonstrated that calcium influx through NMDARs 
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caused CREB activation and expression of neuroprotective BDNF, similar to stimulation 
of L-type calcium channels. However, activation of extrasynaptic NMDARs triggered by 
bath application of NMDA or ischemia caused a dominant CREB inhibition that blocked 
BDNF expression (Hardingham et al., 2002). Furthermore, it has been demonstrated that 
preconditioning doses of NMDA favor activation of synaptic NMDARs by enhancing 
action potential firing and that this is required for both early and late phases of 
preconditioning-neuroprotection (Soriano et al., 2006). This mechanism also involved 
CREB-dependent activation of BDNF. In addition, pharmacologically enhancing 
neuronal activity by a combination of the potassium channel blocker 4-aminopyridine (4-
AP), and the GABA-A antagonist, bicuculline, for 1-2 days resulted in potent and 
prolonged (up to 3 days) elevations in tolerance to simulated ischemia (Tauskela et al., 
2008). This effect correlated with activation of ERK1/2 and CREB and was blocked by 
NMDAR and L-type voltage gated calcium channel antagonists, further confirming the 
role of synaptic neurotransmission in the preconditioning-dependent neuroprotection. 
 
2.14 The NMDA receptor 
The NMDAR is a subclass of excitatory ionotropic glutamate receptors that is 
selectively activated by the synthetic amino acid N-methyl-D-aspartate. These receptors 
are unique among neurotransmitter receptors, since they require the binding of a co-
agonist glycine (or D-serine) along with L-glutamate for activity, have a high degree of 
voltage dependence, have high permeability to calcium, and display slow 
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activation/deactivation kinetics. Voltage dependence is achieved by a magnesium 
blockade of the channel pore at resting membrane potentials that is released upon 
depolarization, often by simultaneous stimulation of the AMPA subclass of ionotropic 
glutamate receptor. The functional NMDAR consists of a heteromeric assembly (most 
likely to be a tetramer, but not yet unequivocally proven) of NR1, NR2 and NR3. Seven 
genes encode for the NMDAR subunits and include NR1, NR2A-D and NR3A-B. Each 
subunit is composed of an extracellular regulatory domain and agonist binding domain, 
four transmembrane spanning domains (M1-4, the M2 domain is actually a membrane re-
entrant domain similar to the selectivity filter of potassium channels) that form the 
channel pore, and an intracellular C-terminal domain. The NR1 subunit contains the 
binding site for the co-agonist glycine, has a short C-terminal domain, and is obligatory 
for receptor function. NR1 undergoes extensive splicing resulting in 8 different splice 
variants NR1-1a,1b to NR1-4a,4b. Of these, NR1-2a,b and NR1-4a,b are missing an ER 
retention signal encoded in the C1 cassette (Standley et al., 2000) and thus exit 
independent of NR2 assembly. The NR2 subunit contains the glutamate binding domain 
and a long C-terminal domain that dictates many channel properties. For example, 
inhibition of NR2B but not NR2A subunit activity sharply reduces LTP and spontaneous 
activity-driven potentiation in hippocampal slice cultures; this is due to the affinity of the 
subunits for CamKII (Barria and Malinow, 2005). Furthermore, both NR1 and NR2 are 
phosphorylated by different serine/threonine kinases and tyrosine kinases. NR1 is 
phosphorylated exclusively on serine residues by the activity of PKA and PKC. PKC 
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phosphorylation of serine 890 of NR1 disrupts NMDAR clustering (Tingley et al., 1997), 
but phosphorylation of serine 890 together with PKA phosphorylation of serine 897 is 
required for increased NMDAR surface expression (Scott et al., 2001) in a mechanism 
involving disruption of an ER retention signal. NR2C is also serine phosphorylated by 
PKA, PKB/Akt, and PKC. NR2A&B are serine and tyrosine phosphorylated by multiple 
serine/threonine and tyrosine kinases. NR2 phosphorylation is more complex, since it 
affects not only localization but also channel properties. For example, PKC 
phosphorylation of NR2A on serine1291 and 1312 enhance channel conductance (Grant 
et al., 2001). However, phosphorylation of NR2B at tyrosine 1472 within its C-terminal 
YKEL sequence, the adaptor protein 2 (AP-2)-interacting motif, disrupts interaction with 
AP-2 which inhibits clathrin-mediated endocytosis and preserves its membrane 
localization (Lavezzari et al., 2003).  
Additionally, phosphorylation of serine 1480 within the C-terminal PDZ ligand 
(IESDV) by casein kinase II disrupts interaction of NR2B with the PDZ domains of post 
synaptic density protein PDS-95 and synapse-associated protein SAP-102, causing 
dissociation from the post synaptic density (Chung et al., 2004). Thus receptor subunit 
composition, post-translational modification and interaction with various modulatory and 
signaling machinery (discussed in more detail later) create a great deal of NMDAR 
functional diversity within the CNS and are hypothesized to account for the diverse roles 
of the receptor in brain development, learning, memory and disease. 
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2.15 Ethanol and the NMDA receptor 
The NMDAR is a well recognized target of ethanol within the CNS. The acute 
effects of ethanol on NMDAR neurotransmission are inhibitory (Chu et al., 1995) and are 
believed to mediate (at least in part) the sedative effects of intoxication. With continued 
ethanol exposure adaptive responses are believed to occur in the brain to compensate for 
the inhibitory effects of ethanol on NMDAR signaling. This compensatory upregulation 
of NMDAR is thought to underlie withdrawal symptoms associated with alcoholism, 
such as tremor and seizures as well as accounting for plasticity changes that occur during 
development of tolerance. For example, in vivo exposure to a 14-day chronic intermittent 
ethanol (CIE) protocol via ethanol vapor chamber caused a marked increase in field 
excitatory postsynaptic potentials (fESPS) of pharmacologically isolated NMDAR-
currents in the CA1 region of acutely isolated hippocampal slices at 7 days post-
withdrawal (Nelson et al., 2005). These electrophysiological changes correlated with 
increased expression of NR2A and NR2B. Furthermore, CIE (75mM for 14 h followed 
by 10 h withdrawal, repeated 5 times), upregulated NR1 and NR2B in cultured cortical 
neurons at days 2 and 5 post-withdrawal (Qiang et al., 2007). The increase was correlated 
with increased surface expression but not endocytosis. The increase in surface expression 
was confirmed by immunocytochemistry and shown to be mainly synaptic, correlating 
with increases in PSD-95 immunoreactive clusters, and was PKA-dependent. Also, 
chronic ethanol (50mM, 4 days, EtOH vapor container) caused significant increases in 
the size and density of synapsin-associated clusters (synaptic marker) containing NR1 
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and NR2B and enhanced synaptic NMDAR mEPSCs in hippocampal neurons via a PKA-
dependent mechanism (Carpenter-Hyland et al., 2004). Finally, ethanol causes increases 
in NR2B phosphorylation in dorsal—but not ventral—striatal slice cultures in a 
mechanism requiring Fyn kinase activity (Wang et al., 2007). This study also 
corroborated Fyn-dependent phosphorylation of NR2B with ethanol-induced long term 
facilitation of NMDAR currents in dorsal but not ventral striatum. In contrast to chronic 
effects of ethanol, acute ethanol exposure has been shown to have the opposite effect on 
phosphorylation of NR2 subunits. Alvestad et al. reported that a 10 min application of 
ethanol (100mM) decreased phospho-NR2B concomitant with decreases in NMDAR 
field excitatory postsynaptic potential slope and amplitude (Alvestad et al., 2003). These 
changes were reduced by co-application of a phospho-tyrosine phosphatase inhibitor. 
 
2.16 Post synaptic density protein 95kD (PSD-95) 
Fidelity in postsynaptic signal transduction requires spatially and temporally 
coordinated organization of signaling machinery. At excitatory synapses this is a highly 
dynamic process that allows for changes in synaptic strength such as LTP and LTD. 
PSD-95 is a member of the membrane associated guanylate kinase (MAGUK) family of 
PDZ domain containing proteins. MAGUK family members share a common structural 
arrangement containing three PDZ (PSD95, Drosophila disc large tumor suppressor and 
Zonula occludens-1 protein) domains, an SH3 domain and a kinase-dead guanylate 
kinase (GK) domain. PSD-95 and other MGAUK proteins are found enriched at 
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postsynaptic densities where they function as scaffolds for transmembrane proteins and 
anchors to the cytoskeleton. Many NR2 subunits of the NMDAR contain a seven amino 
acid carboxy terminal tSXV (serine, any amino acid, valine) motif that binds to the 
second PDZ domain of PSD-95. This interaction facilitates the postsynaptic clustering of 
NMDAR (Kornau et al., 1995). The SH3 domain of PSD-95 is know to associate with 
proline rich regions of non-receptor tyrosine kinases. Furthermore, because PSD-95 
expression increases the number, activity and size of glutaminergic spines, it is a 
suspected modulator of synaptic strength and plasticity (El-Husseini et al., 2000). Support 
for this hypothesis was demonstrated by Delint-Ramirez and colleagues, who found that 
PSD-95 and NMDARs were recruited to synaptic lipid rafts in the hippocampus and 
insular cortex 24h following spatial memory training (Morris water maze), and this 
caused tyrosine phosphorylation of NR2B-Y1472 (Delint-Ramirez et al., 2008). 
Furthermore, NR2B Tyr-1472 phosphorylation is enhanced after induction of LTP in the 
hippocampus (Nakazawa et al., 2006) and fear learning in the amygdala. This study 
suggests that Src-mediated phosphorylation of Tyr-1472 is involved in synaptic 
plasticity. 
PSD-95 interacts with several ion channels, including AMPA, NMDA and 
potassium channels, and facilitates their clustering and interaction with signaling 
machinery at excitatory synapses. Therefore, PSD-95 is believed to be an integral part of 
synaptic development and plasticity. However, mechanisms that govern its ability to 
coordinate ion channel assembly and clustering are only partially understood. PSD-95 has 
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two distinct post-translational modifications that govern its clustering, and both appear to 
depend on synaptic activity—these are phosphorylation and palmitoylation. Early work 
showed that PSD-95 partitions as an integral membrane protein in brain homogenates and 
is thioester-linked to palmitic acid, a 16-carbon fatty acid (Topinka and Bredt, 1998). 
Multimerization of PSD-95 occurs through a unique N-terminal 13 amino acid motif 
which contains two conserved cysteine residues that are the substrates for palmitoylation 
(Christopherson et al., 2003).  
Palmitoylation of PSD-95 is both necessary and sufficient to cause channel 
clustering. Palmitoylation is a reversible reaction catalyzed by protein palmitoyl 
acyltransferases (PATs), which are members of the DHHC (Asp-His-His-Cys) protein 
family. Recently, Noritake and coworkers demonstrated the activity-dependent 
palmitoylation of PSD-95 and determined that DHHC2, a dendritically localized PAT, 
but not DHHC3, a Golgi-resident, mediates the reaction. Specifically, inhibition of 
synaptic activity causes rapid translocation of DHHC2 to postsynaptic densities where it 
acts on PSD-95 to facilitate palmitoylation and subsequent clustering and association 
with ion channels (Noritake et al., 2009).  
In addition to palmitoylation, PSD-95 can be further modified by phosphorylation 
at serine 295. Modification of this type is also activity- dependent and causes 
accumulation of PSD-95 at the postsynaptic density and recruitment of AMPA receptors. 
Phosphorylation of PSD-95 is mediated by the Rac1-JNK pathway and is enhanced in 
response to chronic silencing and inhibited by increases in synaptic activity. Furthermore, 
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chemically-induced LTD by NMDA treatment causes a rapid decrease in ser-295 
phosphorylation, and a phosphomimetic mutant, S295D of PSD-95, inhibited NMDA-
induced AMPA receptor internalization and blunted LTD induction (Kim et al., 2007). 
Thus, the activity-dependent modulation of PSD-95 is dynamic, as is the nature of the 
synapse itself. 
 
2.17 Pyk2 
NMDA receptor activity correlates with protein tyrosine phosphorylation (Rostas 
et al., 1996). The mechanisms responsible for NMDAR tyrosine phosphorylation and 
subsequent increase in activity are only partially understood. Two likely non-receptor 
tyrosine kinases involved in this process are Src-family and Pyk2. Pyk2 is a member of 
the focal adhesion kinase (FAK) family of protein tyrosine kinases, sharing a high degree 
of homology with FAK. Pyk2 has 48% identity and 65% similarity to FAK, and like 
FAK it lacks a transmembrane region, myristoylation sites, and SH2 and SH3 domains 
(Avraham et al., 1995). Also, the focal adhesion targeting (FAT) domain of Pyk2 is 
repressed in most instances (Schaller and Sasaki, 1997). However a striking difference 
between the two is that Pyk2 can be activated by multiple stimuli that increase 
intracellular calcium by both PKC-dependent and PKC-independent pathways (Soltoff et 
al., 1998). Pyk2 contains FREM (band 4.1/ezrin/radixin/moesin homology), kinase, 
proline-rich and focal adhesion targeting (FAT) domains. Furthermore, Pyk2 is 
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autophosphorylated at Tyr-402 during activation. Pyk2 is necessary and sufficient for the 
induction of CA1 LTP, and tetanic stimuli cause activation of Pyk2 (Huang et al., 2001).  
Although Pyk2 is well known to be activated by calcium, the calcium-dependent 
mechanism of Pyk2 activation in postsynaptic densities has remained elusive. Very 
recently, some light has been shed on this matter. Bartos and colleagues report that Pyk2 
is activated via a unique mechanism involving calcium/calmodulin and PSD-95 (Bartos 
et al., 2010). They provide strong evidence that Pyk2 is trans-autophosphorylated in 
response to calcium entry through NMDAR and that this causes postsynaptic clustering 
of Pyk2 and physical interaction with PSD-95. Furthermore, this oligomerization is 
caused by Pyk2 binding to PSD-95, allowing for the close proximity required for trans-
autophosphorylation. The interaction is achieved through the interaction of the SH3 
domain of PSD-95 interacting with the proline-rich domain of Pyk2.  
Bartos et al. (2010) further hypothesize that under basal conditions, the PSD-95 
SH3 domain is bound to the guanalate kinase domain obscuring interaction with Pyk2. 
However, calcium entry through NMDARs causes activation of calmodulin and binding 
of Ca/Calmodulin to the HOOK domain (disorganized linker region between the GK and 
SH3 domain) of PSD-95. This causes displacement of the SH3/GK interaction, allowing 
for binding and clustering of Pyk2 and subsequent trans- autophosphorylation (two Pyk2 
monomers phospho-activate each other in trans). Thus, they provide a plausible 
mechanism accounting for the calcium-induced activation of Pyk2 and provide insight on 
the role of Pyk2 in the induction of LTP in hippocampal CA1 neurons. Furthermore, they 
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show that PKC is not required for Pyk2 activation, since inhibitors of PKC fail to block 
activation. However, activators of PKC do lead to activation of Pyk2 (Siciliano et al., 
1996). 
Pyk2 is also involved in the recruitment of Src to the NMDAR complex. This is 
critical for many of Pyk2’s functions, including induction of LTP, coupling to ERK and 
JNK MAPK pathways, and cerebellar granule cell survival. Specifically, upon activation 
by phosphorylation of Pyk2-Y402, a modification that alleviates Pyk2 autoinhibition, Src 
then binds to Y402 via interaction of its SH2 domain and causes further phosphorylation 
of Pyk2 at Y579 and Y580 of the activation loop, augmenting Pyk2 catalytic activity 
(Avraham et al., 2000). Subsequently, the Pyk2-activated Src phosphorylates NR2 
subunits in the NMDAR complex (Wang and Salter, 1994). Phosphorylation of NMDAR 
by Src upregulates NMDAR function and thus gates NMDAR-dependent synaptic 
potentiation (Salter and Kalia, 2004). Pyk2 acting via Src is necessary and sufficient for 
CA1 LTP. Tetanic stimulation increases the interaction of Pyk2 and Src (Huang et al., 
2001) and this pathway is critical for NMDAR-dependent activation of the ERK MAP 
kinase pathway (Lev et al., 1995). Pyk2 is also critical for the survival of cerebellar 
granule neurons in response to repolarization-induced apoptosis. Dominant-negative 
Pyk2 caused 60% reduction in total neuronal number at 24h post-transfection in granule 
cells cultured in depolarizing conditions (Strappazzon et al., 2007). 
As mentioned above, Pyk2 has several unique characteristics that mediate its 
ability to both instigate cell survival via activation of ERK (Lev, et al., 1995) and 
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transduce neuronal stress/death pathways through its interaction with JNK pathways 
(Tokiwa et al., 1996). Its ability to protect neurons is not limited to its role in the 
NMDAR-ERK pathway. This is because it has also been shown to mediate the 
neuroprotective effect of the transient receptor potential canonical (TRPC) channel. 
Interestingly, Yao and colleagues demonstrated that platelet-derived growth factor 
(PDGF)-mediated neuroprotection was mediated via the TRPC in a Pyk2/ERK/CREB- 
dependent manner (Yao et al., 2009). Specifically, blocking TRPC5 or TRPC6 with an 
inhibitor or siRNA induced suppression of PDGF-mediated neuroprotection in primary 
neurons. Furthermore, PDGF was able to protect dopaminergic neurons in the substantia 
nigra from HIV Tat-induced neurotoxicity. TRPC3 and 6 activation protect cerebellar 
granule neurons from serum deprivation-induced neurotoxicity and promote their 
survival in rat cerebellum (Jia et al., 2007). In vitro inhibition of TRPC3 or 6 suppressed 
BDNF-dependent neuroprotection and CREB activation. Additionally, overexpression of 
these channels enhanced neuronal survival in vivo and in vitro in a CREB-dependent 
manor. 
Pyk2’s capacity to become rapidly activated in response to stressful stimuli, and 
to interact with both ERK and JNK pathways, suggest it may have a role as an 
intermediary in preconditioning-dependent signal transduction cascades. Nevertheless, it 
has been little studied in this regard. One study found an increased phosphorylation of 
NR2A and NR2B after transient (5 min) non-lethal ischemia, concomitant with an 
increased association of PSD-95, NR2B, Pyk2, FAK and Src that peaked at 3h 
37 
 
 
 
reperfusion; with the exception of Pyk2 (which remained elevated in the NMDAR 
complex), they returned to basal levels 72h later. However, these changes were not 
observed with lethal 30 min ischemia (Zalewska et al., 2005). Although the authors of 
this report were not directly investigating ischemic preconditioning, but rather the 
differences between lethal and non-lethal ischemia, their model of non-lethal 5 min 
ischemia is consistent with a preconditioning stimulus. 
 
2.18 Src family non-receptor tyrosine kinases 
Src was first described by Bishop and Varmus in vertebrate tissues as a 
protooncogene based on homology to avian Rous carcinoma virus (Spector et al., 1978). 
Src is the largest family of non-receptor tyrosine kinases with nine members. Of these, 
Src, Fyn, Lyn, Lck and Yes are expressed in the CNS. Src-family kinases are comprised 
of a number of conserved domains, some of which appear frequently in heterologous 
signal-related proteins, including G protein-coupled receptors, receptor tyrosine kinases, 
cytokine receptors and cell-adhesion receptors. Within the Src family, the catalytic Src 
homology domain (SH1), the phosphotyrosine binding SH2 domain, the proline rich-
binding SH3 and amino-terminal domains share high homology. SH2 and SH3 domains 
are examples of common protein-protein interaction motifs found in a variety of proteins 
(Pawson and Scott, 1997). These two domains also bind intramolecularly and are 
responsible for autoinhibition (Xu et al., 1997). Tyrosine 527 of Src is phosphorylated 
and interacts intramolecularly with the SH2 domain (Liu et al., 1993), causing inhibition 
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of kinase activity (Cooper et al., 1986).  Inhibitory intramolecular interaction further 
occurs between the SH3 domain and the linker region connecting SH2 and catalytic 
domains. These interactions are interrupted by binding to sequences in other proteins 
causing activation of Src. Tyrosine 416 in the catalytic domain is autophosphorylated 
(Smart et al., 1981). The SH3 domain binding sequence is a 10 amino acid, proline-rich 
motif containing the consensus sequence pXXp (where X is any amino acid) (Ren et al., 
1993). The N-terminal SH4 domain contains a consensus sequence for lipid 
modifications, such as myristoylation and/or palmitoylation, critical for interaction with 
cell membranes (Resh, 1993). Indeed, Src acts as a central mediator and convergence 
point for a number of critical cellular signaling pathways. 
Src-family kinases have long been known to modulate the activity of ion 
channels. Src was first shown to modulate NMDAR activity in the CNS (Wang and 
Salter, 1994) and then voltage-gated potassium channels (Fadool et al., 1997), L-type 
calcium channels (Cataldi et al., 1996), GABAA receptors (Moss et al., 1995) and 
nicotinic acetylcholine receptors (Wang et al., 2004a). Exogenous Src or a peptide 
activator of Src enhances NMDAR peak currents (Cheung and Gurd, 2001). Src 
coimmunoprecipitates with multiple PSD components (Husi et al., 2000). Src activation 
is necessary and sufficient for inducing LTP and functions by up-regulating NMDAR (Lu 
et al., 1998). Src phosphorylates multiple components of the NMDAR complex, 
including NR2A (Kohr and Seeburg, 1996) and NR2B (Cheung and Gurd, 2001). Thus 
Src-dependent modulation of NMDAR activity is believed to be responsible for many of 
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the physiological processes of the receptor, including LTP (Soderling and Derkach, 
2000), synaptic transmission, and plasticity (Ali and Salter, 2001). 
 
2.19 Peroxiredoxins in neuroprotection and AD 
Peroxiredoxins (prx) are a ubiquitous family of antioxidant proteins that reduce 
and detoxify H2O2, peroxynitrite, and organic hydroperoxides. They are divided into 
three subclasses: typical 2-Cys (2-Cys refers to the catalytic site containing 2 cysteine 
residues, prx1-4), atypical 2-Cys (prx5), and 1-Cys (prx6). All three classes undergo the 
same initial oxidation reaction whereby an oxidant attacks the peroxidatic (undergoes 
initial oxidation, see Fig. 1) cysteine, forming S-hydroxycysteine. The second step for the 
2-Cys peroxiredoxins involves a resolving cysteine (reduces S-hydroxycysteine to form a 
disulfide bond, see Fig.1) that is attacked (oxidized) by the sulfenic acid of the 
peroxidatic cysteine to form a disulfide bond. Typical and atypical 2-Cys peroxiredoxins 
differ in the location of the resolving cysteine residues. The catalytic cysteine residues for 
the typical 2-Cys peroxiredoxins are located on two juxtaposed subunits, which form the 
catalytic site, and when oxidized, result in an intersubunit disulfide bond. This causes 
multimerization and is thought to be involved, in part, in the role of prxs in mediating 
ROS signal transduction (Rhee et al., 2005). Conversely, the catalytic residues of the 
atypical 2-Cys peroxiredoxins residues lie within the same subunit and the oxidation step 
therefore results in an intrasubunit disulfide bond. Finally, oxidation of the peroxidatic 
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cysteine of 1-Cys prx6 is not resolved by a neighboring cysteine and must be reduced by 
some other reducing equivalent (such as glutathione). 
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Figure 1: Mechanism of hydrogen peroxide reduction by peroxiredoxins 
Reduction of hydrogen peroxide (or other ROS) by the peroxiredoxins (prxs) all occurs 
through the same initial reaction. An oxidant attacks the peroxidatic cysteine, forming S-
hydroxycysteine (a sulfenic acid). The second step for the 2-Cys prxs involves a 
resolving cysteine, which is attacked (oxidized) by the sulfenic acid intermediate, 
producing a disulfide bond. The 2-Cys prxs contain two family members, typical and 
atypical. They differ by the location of their resolving cysteine residues. For the typical, 
the resolving cysteine is located on a juxtaposed subunit, and oxidation therefore results 
in intersubunit disulfide bond formation. The atypical has its resolving cysteine on the 
same subunit, and thus oxidation results in formation of an intrasubunit disulfide bond. 
The 1-Cys prx has no resolving cysteine and thus reduction of its S-hydroxycysteine must 
be by some other reducing equivalent such as glutathione. 
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Reduction and thus reactivation of the 2-Cys peroxiredoxins occurs mainly 
through the thiol-reducing thioredoxin/thioredoxin reductase system, which utilizes 
reducing equivalents from NADPH and is coupled to the pentose phosphate pathway 
(Wood et al., 2003).  However, the disulfide bond formation is slow and thus the sulfenic 
acid intermediate can be further oxidized to sulfinic and sulfonic acids. This process was 
thought to be irreversible, but more recently it was shown that it is reversible by the ATP-
dependent activity of sulfiredoxin for the typical 2-Cys prxs (Woo et al., 2005). 
Peroxiredoxins are prevalent antioxidant enzymes in the CNS and also show 
distinct subcellular, cellular and anatomical distribution profiles. Prx1, prx2, and prx6 (1-
Cys) appear mainly in the cytosol, whereas prx3 is primarily mitochondrial and prx4 is 
secreted (Wood et al., 2003). Prx5 (atypical 2-Cys) shows a more widespread 
localization, including cytosol, mitochondria, and peroxisomes (Seo et al., 2000). 
Furthermore, whereas neurons show moderate staining for prx2-5, oligodendrocytes 
show robust staining for prx1 and 4 and moderate reactivity of prx6 (Jin et al., 2005). 
Also, in this study, prx1 was shown to be primarily microglial, whereas prx6 was found 
in astrocytes. These results contrast with an earlier study that showed prx1 was expressed 
primarily in astrocytes, while prx2 was expressed exclusively in neurons in cerebral 
cortex, cerebellum, basal ganglia, substantia nigra, and spinal cord (Sarafian et al., 1999). 
Nevertheless, the distinct subcellular, cellular and anatomical distribution of these 
antioxidant enzymes within the CNS implies differential and important roles for CNS 
function. 
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Since first being characterized (Chae et al., 1994), this thiol-specific antioxidant 
family has rapidly gained notoriety for its role in cytoprotection and disease. Prx isoforms 
have been shown to have aberrant expression in certain diseases such as AD, Parkinson’s 
disease, Down’s syndrome (Krapfenbauer et al., 2003), Creutzfeldt-Jacob disease 
(Krapfenbauer et al., 2002), and ALS (Kato et al., 2005). Furthermore, prx2 is 
upregulated in AD brain and in 2 transgenic mouse models of AD, and transfection with 
prx2 protects cultured cortical neurons from toxic Aβ (Yao et al., 2007). These authors 
propose that prx2 is a marker for early AD and provide evidence that the interaction 
between amyloid-binding alcohol dehydrogenase and Aβ mediates up-regulation of prx2. 
They propose that blocking this interaction could be a therapeutic target; however, this is 
not likely the sole pathway for AD-associated ROS, and it remains to be determined if 
blocking this association will have beneficial outcomes in vivo.   
An additional study showed overoxidation of prx2 in AD brain (Cumming et al., 
2007). Furthermore, they show that a neuronal-like cell line (PC12) that has been 
developed for resistance to Aβ has increased expression of prx1, 2 & 6. Prx2 is 
phosphorylated on threonine 89 in a calpain/p35/Cdk5-dependent mechanism in response 
to MPP+ and/or MPTP (mitochondrial stress) and this causes inhibition of its peroxidase 
activity (Qu et al., 2007). Furthermore, a phospho-mimetic mutant was more sensitive to, 
and a phospho-null mutant protected against, mitochondrial stress in vitro and in vivo.  
Additionally, prx2 has been shown to mediate, at least in part, the neuroprotective effects 
of pituitary adenylate cyclase activating polypeptide in cultured cerebellar granule 
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neurons (Botia et al., 2008). They further show that prx2 expression is induced by both 
cyclic AMP and PKC stimulators, and also show upregulation of prx2 with exposure to 
325 mM EtOH in vitro and 2.5 g/kg in vivo that peaks at 24h of exposure; it is of note 
that the in vitro concentration is an extremely high level of EtOH. They further speculate 
on prx2’s therapeutic potential for the treatment of some neurodegenerative diseases. 
Finally, as mentioned above, thioredoxin (trx) is critical in the maintenance of prxs in the 
reduced state and thus their ability to function as antioxidant enzymes. In this regard, it 
has been demonstrated that trx overexpressing mice show resistance to focal ischemia, a 
known ROS-dependent neurodegenerative insult (Takagi et al., 1999). 
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CHAPTER THREE 
MATERIALS AND GENERAL METHODS 
3.1 Chemicals and antibodies 
Hoechst 33342, propidium iodide (PI), DL-2-amino-5-phosphonopentanoic acid 
AP-5, 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), pertussis toxin, memantine, 
NMDA, deoxyribonuclease I (DNAse), Tween 20, Triton-X 100, protease and 
phosphatase inhibitor cocktails, and penicillin/streptomycin were from Sigma Co. (St. 
Louis MO). Neurobasal-A media, B27, trypsin and fetal bovine serum (FBS) were from 
Gibco (Carlsbad, CA). American Peptide (Sunnyvale, CA) provided Aβ25-35 and Aβ35-
25. Polyacrylamide gels were obtained from GenScript (Piscataway, NJ). Western blot 
buffers and enhanced chemiluminescence detection (ECL) solutions were from Pierce 
Chemical Co. (Rockford, IL). The antibodies obtained from Upstate Co. (Temecula, CA) 
were anti-NR1-CT  (1:1000) and anti-NR2B (1:1000); from Chemicon International 
(Temecula, CA), anti-NR2C (1:1000), PSD-95 (1:1000), NR2B-pY1472 (1:1000), 
neuronal specific nuclear antigen (NeuN, 1:1000) and glial acidic fibrillary protein 
(GFAP, 1:1000); and from Cell Signaling (Danvers, MA), actin (1:1000) and horseradish 
peroxidase (HRP)-conjugated anti-rabbit IgG (1:1000-1:20,000). 
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3.2 Cerebellar mixed primary cultures  
The culture protocol is modified from (Brewer et al., 1993). 7-10 day old 
Sprague-Dawley rat pups are cryoanesthetized on ice for 2-3 min and rapidly decapitated. 
The brain is carefully removed and placed into ice-cold Gays balanced salt solution 
(GBSS) supplemented with 4.5 mg/ml glucose. The cerebellum is then carefully removed 
and placed into ice cold minimal essential media (MEM) supplemented with 6.5 mg/ml 
glucose. Meninges are removed and the cerebella are sectioned manually into 
approximately 6 pieces. Pieces are then transferred into calcium- and magnesium-free 
Hanks balanced salt solution (CM-HBSS) containing 0.25% trypsin and 0.5 mg/ml 
DNAse at 37°C. Tissue is incubated for 10 min, and pieces are transferred into MEM 
with 10% fetal bovine serum (FBS) and 5% horse serum (HS) to inactivate trypsin. Cells 
were dispersed by triturating with two fire polished pipettes that have decreasing size. 
Next, cells are passed through a 70µm cell strainer. Viable cell density is determined by 
trypan blue exclusion on a hemocytometer. Cells are diluted to a concentration of 
800,000 cells/ml in serum-free Neurobasal-A media supplemented with 2% B27 (Gibco), 
500µM L-glutamine and 1% penicillin-streptomycin. Cells are then plated on poly-L 
lysine- coated 12 well plates at 1 ml/well. All of the media is changed after one hour. 
Half of the media is changed every three days until DIV10, at which point 100% of the 
media is changed. This technique allows glia to proliferate to near confluence and 
produces neurons with robust processes and intricate neural networks (see Fig. 2B). 
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3.3 Ethanol pretreatment and Aβ exposure  
Culture media is changed to media containing 30mM ethanol (1.8µl EtOH/1ml 
media) or media alone. Culture plates containing ethanol are placed in airtight containers 
that have small open dishes of 90mM ethanol to minimize evaporative ethanol loss from 
experimental wells. Ethanol levels will be monitored via Sigma NAD-ADH reagent 
multiple test reagent (product number N 7160). Control plates are treated similarly, but 
with water alone. The container is allowed to equilibrate with incubator atmosphere for 
15 min and then sealed. Culture media and solution dishes are changed at day 3. At day 6, 
100% of ethanol media or control media is removed and media with or without 25µM Aβ 
(25-35) is added. For drug treatments, a parallel set of plates is prepared, differing only 
by the presence of added drug.  
 
3.4 Lactate dehydrogenase assay 
Media were collected from cultures and spun at 5000g for 5 min. The 
manufacturer’s microplate protocol was used to determine toxicity. Lactate 
dehydrogenase (LDH) activity correlated linearly (R2 = 0.9992; see Fig. 2) with the 
number of live cerebellar cells lysed over the activity ranges in these experiments. 
Neurotoxicity is reported as LDH activity/100µL culture media. 
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Figure 2: Positive control for LDH assay 
Cerebellar cells were trypsinized and manually dissociated via triturating with a fire 
polished pipette, counted with a hemocytometer and diluted to the indicated cell 
concentration. Cell suspensions were then lysed by addition of 1% Triton-X100 and 
assayed for LDH activity. Regression data are represented over LDH activity ranges 
observed in experiments. Four cell concentrations are shown covering ~300-300,000 
cells/ml, and  n=3 for each concentration. 
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3.5 Analyses of cytotoxicity by Hoechst/PI staining  
Cerebellar cell cultures were incubated 15 min at 37°C with 5 µM Hoechst 33342, 
which labeled nuclei of all cells, and 5 µg/ml propidium iodide (PI), which stained 
dead/dying neurons. The extent of cytotoxicity defined as percent of dying neurons was 
obtained by dividing the number of PI-positive neurons by the total number of Hoechst-
stained nuclei and multiplying by 100. Approximately 500 nuclei were counted per well 
and six wells per experimental group. Images were subsequently analyzed with NIH 
ImageJ 1.34s (NIH, Bethesda, MD, USA).  Note: NMDA preconditioning is not 
neurotoxic as determined by this method (Fig. 3). 
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Figure 3: NMDA preconditioning is not neurotoxic in cerebellar mixed cultures 
 Cerebellar cultures 13DIV were treated with the indicated concentrations of NMDA for 
24h and assayed for viability via dual fluorescence staining with Hoechst 33342 (staining 
all nuclei) and PI (staining dead/dying cells). Data shown as means +/- sem, n = 6.   
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3.6 Western blot analyses  
Protein (5-20µg) from cellular extracts was loaded and run on 4-12% 
polyacrylamide gels. After separation, protein was transferred to polyvinylidene fluoride 
(PVDF) membrane. Membranes were blocked with 1 or 3% BSA in TBS with 0.1% 
Tween 20 for 60 min. Primary antibody was diluted based on manufacturer’s 
recommendation in 1 or 3% BSA TBS with 0.1% Tween 20. Membranes were incubated 
at rt for 60 min or overnight @ 3°C. HRP-conjugated secondary antibody was added in 
TBS with 0.1% Tween 20 for 2h. Membranes were then incubated with developing 
buffer and exposed to X-ray film. Following development, films were scanned and 
analyzed with NIH ImageJ 1.34s. Unless otherwise stated, actin was used to normalize 
loading. 
 
3.7 Immunocytochemistry for identification of cell types  
Following ethanol or control treatment, cultures were washed 2 times with pre-
warmed phosphate-buffered saline (PBS), fixed for 15 min at 37°C with 4% 
paraformaldehyde, and stored in PBS containing 0.05% NaN3 for later viewing. 
Monolayers were permeabilized with PBS containing 0.3% Triton X-100 and blocked 
with 5% serum of secondary antibody host for 3 h at 27°C. Primary antibodies were 
incubated overnight at 4°C in blocking buffer, washed, and incubated with corresponding 
biotinylated secondary antibody. Streptavidin-conjugated cyanine dye (Cy2 or Cy3, 
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1:200) was then applied for 2 h at 27°C, washed, and stored in PBS containing 0.05% 
NaN3. Primary delete experiments showed specificity of cell-type antibodies. Cultures 
were digitized on an inverted epiluminescent fluorescent microscope equipped with a 
Nikon digital camera (Nikon Inc., Melville, NY, USA) for image acquisition. Images 
were subsequently analyzed with NIH ImageJ 1.34s. 
 
3.8 Deconvolution microscopy 
Cerebellar cultures were grown on 18mm acid-washed glass coverslips coated 
with poly-L lysine. At 10DIV, cultures were treated with 30mM ethanol (MEP) or 
control (C) media for 6 days and then fixed with a cocktail of 100mM PIPES buffer pH 
6.8 with 4% formaldehyde. Monolayers were then permeabilized/blocked in PBS with 
0.1% Triton-x and 10% normal goat serum for 3 h. Following permeabilization/blocking, 
the primary antibodies were diluted to the appropriate concentrations in the same 
perm/block cocktail, with the exception of addition of 5µM Hoechst33342 (used to 
visualize nuclei), and incubated overnight in the dark at room temperature. Primary 
antibody dilutions were as follows: chicken α-βIII tubulin, 1:500; mouse α-PSD-95, 
1:200; and rabbit α-pan NR2, 1:500. Next, coverslips were rinsed 3 times with PBS 
containing 0.1% Triton-X100 and stained with the appropriate secondary antibodies (Cy2 
conjugated  α-rabbit, Cy3 α-chicken, and Cy5 α-mouse; all goat at 1:400) for 1 h and 
washed times.  
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 After the final rinse, coverslips were mounted with fluoro-gel antifaden (to 
minimize photo bleaching) and dried for immediate imaging. Image stacks were collected 
blindly on a Delta Vision deconvolution microscope (60X objective). Deconvolved 
image stacks were then rendered in 3D and quantified with Imaris 6.3.1. An algorithm 
was constructed using Imaris by first selecting the PSD-95 channel (that was not visible 
at the time of data collection, since Cy5 emission spectrum is invisible to the naked eye) 
and inclusion criteria were set for PSD-95 immunoreactive surfaces. This same algorithm 
was then used to analyze all subsequent image stacks and retrospectively analyzed for 
statistical significance using either Systat 11.00.01 or GraphPad Prism 5. At least 20 
neurons were counted per group. 
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CHAPTER FOUR 
RESULTS 
 
4.1 Reductions in dose-related Aβ neurotoxicity by moderate ethanol 
preconditioning (MEP) in mixed cerebellar cultures 
4.1.1 Introduction 
Our laboratories have shown that MEP protects against Aβ-induced neurotoxicity 
in hippocampal-entorhinocortical slice cultures (Belmadani et al. 2004). In order to 
explore in more detail the neuromolecular mechanisms responsible for this apparent 
neuroprotection, I employed cerebellar mixed cultures as a model system. This in vitro 
system is advantageous for several reasons when compared to the HEC slice model. One, 
it allows for relatively high throughput screening of pharmaceuticals that help to identify 
signaling mechanisms (e.g., cell surface receptors) underlying MEP-neuroprotection, and 
may mirror other preconditioning paradigms. Second, it allows high resolution 
immunocytochemical analysis of neurons and glia within the cultures to aid in identifying 
cellular and molecular differences between groups that may account for the observed 
neuroprotection. Finally, these cultures respond with robust and highly reproducible 
MEP-dependent neuroprotection from amyloid neurotoxicity. 
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4.1.2 Results 
Figure 4A, left column, shows phase contrast micrographs of control (top) and 
MEP-treated (bottom) cerebellar cultures. MEP treatment does not seem to affect the way 
these cultures appear. Right column, images show neuronal (NeuN+, top) and glial 
(GFAP+, bottom) cell types present in these cultures. Arrows indicate neuronal cells 
based on morphology that stain positive for NeuN but negative for GFAP. These results 
show both neurons and astrocytes are present in these cultures at the time of Aβ exposure. 
Figure 4B is a schematic representation of our MEP protocol. Mixed cerebellar cultures 
are grown for 10 days and exposed to 30mM ethanol or control media for an additional 6 
days. Following MEP or control treatment, mixed cerebellar cultures contain ~15-20% 
NeuN-positive neuronal cell types and a mixture of non-neuronal, primarily GFAP-
positive cell types (Fig. 4C). MEP treatment affects neither the neuronal viability (Fig. 
4C) nor the total cell number of these cultures (not shown). At 16DIV, MEP untreated 
cultures displayed dose-related Aβ25-35 neurotoxicity (Fig. 4D, 25 µM for 24 hr). The 
toxicity due to Aβ25-35 is significantly counteracted in ethanol-preconditioned cultures 
(Fig. 4E) as determined by released LDH. As expected, the reverse peptide Aβ35-25 (25 
µM) was not neurotoxic (results not shown). Interestingly, our laboratory frequently 
observes a neuroprotective effect of MEP even from toxicity associated with general 
media change in the MEP-treated vs. control groups. A similar effect has been observed 
in HEC slice cultures (Thomas and Morrisett, 2000). 
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Figure 4: Cerebellar mixed cultures, dose-related Aβ neurotoxicity and 
neuroprotection by moderate ethanol preconditioning (MEP) 
 A. Left column: phase contrast micrographs of control (top) and MEP-treated (bottom) 
cerebellar cultures (16DIV). Note: upon visual inspection there appears to be little 
difference between control and MEP-treated cultures.  Right column: images show 
neuronal (NeuN+, top) and glial (GFAP+, bottom) cell types present in these cultures. 
Arrows indicate neuronal cells based on morphology, that stain positive for NeuN but 
negative for GFAP. B. MEP protocol: cerebellar cultures (10DIV) were treated with 
30mM EtOH or control media for 6 d, rinsed and exposed 24 hr to 25µM Aβ25-35 or 
vehicle. C. MEP did not alter neuronal composition of cerebellar cultures. Cerebellar 
cultures were treated as in B and the percent of total (Hoechst 33342-positive) cells that 
are positive for NeuN were quantified in MEP and control treated cultures (n=3 at least 
100 cells counted per well). D. Dose-related neurotoxicity of cerebellar cultures (16DIV) 
to Aβ25-35 as measured by LDH release; *p<0.05 vs. no Aβ25-35 (n=6). E. Aβ 
neurotoxicity in cerebellar cultures was prevented by MEP. *p<0.05 vs. control; 1-way 
ANOVA with Scheffe post hoc test (n = 6). 
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4.1.3 Discussion 
The phase contrast micrographs depicted in Figure 4A indicate that MEP appears 
by visual inspection not to be neurotoxic. This possibility was confirmed by 
immunocytochemical analyses (Fig. 4C) showing that MEP does not alter the neuronal 
composition of the cultures nor the total number of cells (not shown). This is an 
important control, since the reduction in LDH release in MEP-treated vs. cultures could 
be due to a decrease in the number of neurons present at the time of amyloid exposure. 
Next, MEP naive cultures respond with dose-related toxicity in response to amyloid 
challenge (Fig. 4D) and are robustly resistant to this toxicity following MEP treatment 
(Fig. 4E), indicating that these cerebellar cultures are a satisfactory model system to 
study the neuromolecular mechanisms that induce neuroprotection from Aβ by MEP.  
Furthermore, although the cerebellum is relatively resistant to amyloid peptides in vivo 
(Kim et al., 2003), cerebellar granule neurons have been shown to be vulnerable to Aβ in 
vitro  (Allen et al., 1999). Aβ 25-35, employed as the amyloid insult throughout these 
experiments, appears to act via a mechanism identical to the most neurotoxic form in 
vivo, Aβ 1-42 (Frozza et al., 2008).  
LDH activity is commonly used as a measurement of Aβ-induced neurotoxicity 
both in purified (Koh and Choi, 1987;Khan et al., 2007) and mixed neuronal cultures 
(Hartley et al., 1999). Furthermore, LDH release correlates with mitochondrial-driven 
neuronal death (Deshpande et al., 2006). Finally, although both MTT and LDH assays are 
effective measurements of mitochondrial-driven apoptosis, LDH is the more accurate 
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assay, as it is independent of mitochondrial function and is therefore a better endpoint 
measurement of neuronal apoptosis (Lobner, 2000). 
 
4.2 NMDAR-dependency of moderate ethanol preconditioning-induced 
neuroprotection 
 
4.2.1 Introduction 
 Common among preconditioning paradigms is the activation of at least one class 
of cell surface receptor. Soon after its discovery, ischemic preconditioning (IP) of brain 
was found to be dependent on the activity of the NMDAR (Kato et al., 1992). Since then 
several models of preconditioning have demonstrated the role of NMDAR in mediating 
neuroprotection (Jiang et al., 2005). In a rat model of ischemic preconditioning (IP), 
inhibition of NMDAR signaling blocked ERK5 activation, an effect that reversed 
hippocampal CA1 neuroprotection (Wang et al., 2006). That same study showed 
inhibition of ERK5 with antisense oligonucleotide also prevented neuroprotection, 
demonstrating dependence on NMDAR-mediated ERK5 activation for IP. 
Activation of Gαi protein-coupled receptors is one of the earliest signals in the 
induction of IP-mediated protection in heart. Adenosine is an established mediator of IP 
in the heart and in the brain (Heurteaux et al., 1995). In heart, adenosine (Liu et al., 
1991), bradykinin (Goto et al., 1995), and opioids (Bell et al., 2000) signal through Gαi 
protein-coupled receptors and are capable of stimulating preconditioning-mediated 
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protection. Therefore I investigated the role of these receptors in MEP’s neuroprotective 
mechanism. 
 
4.2.2 Results 
To ascertain if adenosine/Gαi/o protein-coupled receptors and/or NMDAR, both 
cell surface receptors implicated in other forms of brain preconditioning neuroprotection, 
are indeed involved in MEP neuroprotection, this experiment examined whether 
antagonism of these receptors reduced or prevented Aβ neurotoxicity. Figure 5 shows 
that, when present in culture media for the first 3 days of preconditioning, neither the 
specific adenosine A1 receptor antagonist, DPCPX (Fig. 5A), nor the Gαi/o protein-
coupled receptor inhibitor, pertussis toxin (Ptx, Fig. 5B), significantly counteracted 
neuroprotection from Aβ after 6 days of MEP. Pertussis toxin inhibits all Gαi/o protein-
coupled receptors, several of whom have been implicated in multiple preconditioning 
paradigms in brain and heart (see Introduction). It is important to note that, although 
somewhat toxic to these cultures based on the reduced total LDH values observed, 
pertussis toxin had no effect on MEP’s neuroprotective mechanism. However, AP-5, a 
highly specific NMDAR antagonist, completely abolished the neuroprotective effects of 
MEP (Fig. 5C). Furthermore, memantine, a moderate affinity NMDAR open channel 
blocker, antagonized most of the MEP neuroprotection (Fig. 5D). These results are 
consistent with the relatively early “sensor” role of the NMDAR in MEP’s 
neuroprotective mechanism and further support the importance of this receptor in 
multiple forms of brain preconditioning. 
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Figure 5: MEP-neuroprotection abolished by NMDAR antagonists, unaffected by 
antagonists of adenosine A1 receptors or Gi/o protein-coupled receptors 
 MEP of cerebellar cultures (as in Fig. 4) was performed with the respective receptor 
antagonists present for the first three days of the 6d MEP protocol, followed by 25 µM 
Aβ 25-35 or vehicle for 24 h. After the 24 h exposure to Aβ, media LDH activity was 
assayed. A. DPCPX (100 nM), adenosine A1 receptor antagonist, did not prevent MEP 
neuroprotection. B. Pertussis toxin (Ptx, 50 ng/ml), Gi/o protein-coupled receptor 
antagonist, also did not alter MEP neuroprotection. C. AP-5 (50 µM), NMDAR 
antagonist, completely abolished MEP neuroprotection. D. Memantine (50 µM), 
NMDAR antagonist, significantly inhibited MEP neuroprotection. *p<0.001 vs. control; 
#p<0.001 vs. MEP; 1-way ANOVA with Scheffe post hoc test (n = 6). 
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4.2.3 Discussion 
The results of these studies implicate NMDAR activation—but rule against 
adenosine A1 or other Gαi/o protein-coupled receptors—in attaining the neuroprotected 
phenotype due to MEP. Whereas inhibition of the adenosine A1 receptor with the 
selective antagonist DPCPX or of Gαi/o protein-coupled receptors with pertussis toxin 
failed to block MEP neuroprotection, inhibition of NMDARs with either the selective 
antagonist AP5 or open channel blocker memantine effectively blocked it. These results 
are seemingly counterintuitive, since ethanol even at low concentrations is a well-known 
inhibitor of the NMDAR (Chu et al., 1995). Therefore, I chose to confirm the ability of 
NMDAR stimulation to induce neuroprotection from Aβ via NMDA preconditioning and 
to study in more detail the mechanism in which MEP is acting through the NMDAR to 
engender the neuroprotective phenotype. 
 
 
4.3 Neuroprotection from Aβ toxicity by NMDA Preconditioning as determined by 
dual fluorescence staining  
 
4.3.1 Introduction 
 Data in Figure 5 identify the role of NMDARs early in the mechanism of MEP-
dependent neuroprotection. This is consistent with other forms of preconditioning. 
Furthermore, exposure of murine cortical cell cultures to preconditioning doses of 
glutamate or NMDA has been shown to be neuroprotective (Grabb and Choi, 1999). 
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Similarly, exposure of cerebellar granule cell cultures to sub-excitotoxic concentrations 
of NMDA has been shown to cause neuroprotection attributable to release of BDNF 
acting on TrkB (Marini et al., 1998). Both NMDA and BDNF exposure result in 
activation of the transcription factor NF-κB. Further, inhibition of NF-κB with an 
oligonucleotide decoy reversed neuroprotection in this model (Wu et al., 2005). 
Neuroprotection in this model correlates with expression of anti-apoptotic bcl-2. 
NMDAR activation is also associated with MAPK activity. Moreover, it has been 
demonstrated that preconditioning doses of NMDA favor activation of synaptic 
NMDARs by enhancing action potential firing and this is required for both early and late 
phases of preconditioning-neuroprotection (Soriano et al., 2006). This mechanism also 
involved CREB-dependent activation of BDNF. In addition, pharmacologically 
enhancing neuronal activity by a combination of the potassium channel blocker 4-
aminopyridine and the GABAA antagonist bicuculline for 1-2 days resulted in potent and 
prolonged (up to 3 days) elevations in tolerance to simulated ischemia (Tauskela et al., 
2008). This effect correlated with activation of ERK1/2 and CREB and was blocked by 
NMDAR and L-type voltage gated calcium channel antagonists, further confirming the 
role of synaptic neurotransmission in the preconditioning-dependent neuroprotection. 
 
4.3.2 Results  
If NMDAR activation is an essential early event in MEP neuroprotection, I 
hypothesized that direct stimulation of this receptor via NMDA preconditioning should 
elicit similar protection from Aβ insult in our cultures. As shown in Figure 6A, cultures at 
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DIV13 were preconditioned with 50µM NMDA for 24h (determined to be subneurotoxic, 
see Fig. 3) and then exposed for 24h to 12.5µM Aβ 25-35 or media only. The DIV13 time 
point represents a culture age corresponding to halfway through the MEP exposure and 
was chosen based on this and our previous work indicating that both subclasses (NR1 and 
NR2) of NMDAR subunits were expressed at that time. In Figure 6B are representative 
live-cell photomicrographs of dual fluorescence staining with Hoechst 33342 and 
propidium iodide (PI), a combination shown to correlate well in cerebellar cultures with 
other cytotoxic measures (Bachis et al. 2003). Hoechst 33342 labels the nuclei of all cells 
and PI stains dying/dead neurons in the control (C) and NMDA-preconditioned cultures. 
PI-stained cell densities between control and NMDA-preconditioned groups did not 
differ, verifying that NMDA treatment was not neurotoxic. However, cultures treated 
with Aβ demonstrated increased density of PI-labeled degenerating neurons compared to 
C or NMDA, whereas the NMDA-preconditioned cultures treated with Aβ (NMDA+Aβ) 
displayed robust neuroprotection from Aβ toxicity. Figure 6C is a quantification of these 
results. Thus NMDAR activation by NMDA ligand binding or, by extension, ethanol 
preconditioning-augmented NMDAR activity, promotes a neuroprotected state in these 
cerebellar cell cultures, rendering them resistant to Aβ insult. 
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Figure 6: Neuroprotection from Aβ toxicity by NMDA preconditioning as 
determined by dual fluorescence staining with Hoescht 33342 and PI 
 A. Cerebellar cultures (13DIV) were treated for 24h with NMDA (50µM) or control 
media followed by 24h ± 25µM Aβ 25-35. B. Representative images of neurotoxicity 
assayed by live cell dual fluorescence staining. C. Quantification of Aβ 25-35 
neurotoxicity (% Hoescht stained nuclei that are PI-positive) in NMDA-preconditioned or 
control cultures. *p<0.001 vs. control; 1-way ANOVA with Scheffe post hoc test (n = 6). 
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4.3.3 Discussion  
The fact that preconditioning with subneurotoxic NMDA ligand itself affords 
neuroprotection from Aβ in our cerebellar cultures lends additional support to the 
possibility that NMDAR activation mediates moderate ethanol-initiated prosurvival 
signaling, and is consistent with NMDA preconditioning/neuroprotection results using 
other primary cultures (Soriano et al. 2006; Smith et al. 2008). NMDAR excitability 
appears critical as well in preconditioning with glutamate or prolonged elevations in 
electrical activity, since NMDAR antagonists block the resultant neuroprotection against 
subsequent ischemia (Lin et al. 2008; Tauskela et al. 2008). However, despite these 
findings, it should be acknowledged that NMDA’s protective mechanism and ethanol’s 
mechanism of neuroprotection may differ in other ways. 
 
 
4.4 Elevation of NMDAR subunits by ethanol preconditioning and abrogation of 
potentiation of obligatory NR1 subunit by memantine 
 
4.4.1 Introduction 
The NMDAR is a well recognized target of ethanol within the CNS. The acute 
effects of ethanol on NMDAR neurotransmission are inhibitory (Chu et al., 1995). 
However, chronic ethanol has been shown to increase NMDAR expression and activity. 
Exposure in vivo to chronic intermittent ethanol (CIE) increases fESPS of 
pharmacologically isolated NMDAR in the CA1 region of acutely isolated hippocampal 
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slices (Nelson et al., 2005). These electrophysiological changes correlated with increased 
expression of NR2A and NR2B. Furthermore, CIE upregulates NR1 and NR2B in 
cultured cortical neurons (Qiang et al. 2007). The increase was correlated with NMDAR 
surface expression but not endocytosis. Surface expression was confirmed by 
immunocytochemistry and was shown to be mainly synaptic, correlating with increases in 
PSD-95 immunoreactive clusters. Also, chronic ethanol causes significant increases in 
the size and density of synapsin-associated clusters containing NR1 and NR2B, and 
enhanced synaptic NMDAR mEPSCs in hippocampal neurons (Carpenter-Hyland et al., 
2004). Finally, a recent in vivo study demonstrated improved memory in rats chronically 
fed moderate, but not high, ethanol-containing diets (Dewachter et al., 2009). This effect 
was hippocampal NR1-dependent, since hippocampal infusion of siRNA directed against 
NR1 abolished ethanol’s facilitatory effects on cognition, and hippocampal NR1 over-
expression mimicked the effects.  
 
4.4.2 Results 
Data in Figure 5 indicate NMDAR involvement early in MEP’s neuroprotective 
mechanism. Therefore, I examined whether changes in the levels of NMDAR subunits 
could underlie increases in receptor activity. Data in Figure 7 demonstrate that NR1, the 
obligatory subunit for NMDAR function, and NR2B and NR2C, which contain glutamate 
binding domain(s), were each significantly elevated by day 2 of ethanol exposure and 
remained elevated after 6 days of preconditioning (Fig. 7A and Fig. 7B). The elevation of 
NMDAR subunits at day 4 in ethanol preconditioning is not shown for simplicity. It was 
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also apparent that co-treatment with memantine antagonist, which counteracts MEP 
neuroprotection from Aβ and restores the peptide’s neurotoxic effects (Fig. 5D), 
completely prevented the 2 day elevations in the obligatory NR1 subunit (Fig. 7A and 
Fig. 7B). 
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Figure 7: Significant increases in NMDAR subunits by day 2-6 of ethanol 
preconditioning and prevention of obligatory NR1 subunit increases with 
memantine 
 Cerebellar cultures (10DIV) were treated with 30mM ethanol or control media for 2d or 
6d; protein extracts were subjected to immunoblot analysis. A. Representative 
immunoblots of NMDAR subunits NR1, NR1 with 45µM memantine, NR2B and NR2C 
after ethanol (E) or control (C) media treatment.  B. Quantification of NR immunoblot 
analyses normalized to actin and expressed as % control. *p<0.05 vs. control by student 
t-test (n = 3-6). 
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4.4.3 Discussion 
 Ethanol is known to acutely inhibit and chronically potentiate NMDAR 
currents, although exact mechanisms remain a matter of intense investigation (Nagy 
2008). I find that persistent increases in subunits NR1, NR2B and NR2C occur by the 
first 2 days of moderate ethanol exposure. Such increases in receptor subunits could be a 
principal reason for increased NMDAR activity leading to neuroprotection. This 
possibility was supported by the fact that memantine blocked the ethanol-dependent 
increases in NR1, the receptor’s obligatory subunit—thus lessening NMDAR activity—
concurrent with abolishing MEP neuroprotection. Of obvious relevance to these in vitro 
findings are in vivo studies demonstrating improved NR1-dependent memory 
performance in rats chronically fed moderate ethanol-containing diets (Kalev-Zylinska 
and During 2007). RNA interference knockdown of hippocampal NR1 abolished 
ethanol’s facilitatory effects on cognition, while NR1 overexpression mimicked ethanol’s 
effects. Thus, although NR2 subunits are known ethanol targets (Woodward et al. 2006), 
changes in NR1 subunits often mirror NMDAR function.  
 
4.5 Increased synaptically-localized NMDAR indicated by NR2B phosphotyrosine-
1472 and PSD-95 after 2 days of ethanol preconditioning  
 
4.5.1 Introduction 
Synaptic NMDAR activity has been correlated with activation of pro-survival 
signaling within neuronal populations. Phosphorylation of NR2B at tyrosine 1472 within 
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its C-terminal AP-2-interacting motif preserves its membrane localization (Lavezzari et 
al., 2003). Additionally, PSD-95 expression increases the number, activity and size of 
glutamatergic spines and is a suspected modulator of synaptic strength and plasticity (El-
Husseini et al., 2000). Support for this was demonstrated by Delint-Ramirez and 
colleagues. This group found that PSD-95 and NMDAR were recruited to synaptic lipid 
rafts in the hippocampus and insular cortex 24h following spatial memory training 
(Morris water maze) and this caused tyrosine phosphorylation of NR2B-Y1472 (Delint-
Ramirez et al., 2008). Furthermore, NR2B Tyr-1472 phosphorylation is enhanced after 
induction of LTP in the hippocampus and fear learning in the amygdala (Nakazawa et al., 
2006). This study suggests that Src-mediated phosphorylation of Tyr-1472 is involved in 
synaptic plasticity. Therefore, I chose to investigate if there were changes in these 
markers of synaptic NMDAR complex early in the ethanol preconditioning protocol. 
 
4.5.2 Results 
Questioning whether MEP-induced NMDAR activity was primarily synaptic, and 
considering recent reports on the critical importance of synaptic vs. extrasynaptic 
localization on NMDAR pro-survival signaling, I examined ethanol’s effects on levels of 
tyrosine 1472-phosphorylated NR2B (NR2B-pY1472) and PSD-95 relatively early in the 
6 day preconditioning protocol. The activity and synaptic localization of NMDAR are 
believed to require phosphorylation of subunits, especially tyrosine 1472 of NR2B 
subunit, by Src family tyrosine kinases (Yu et al. 1997; Goebel-Goody et al. 2009). Also, 
PSD-95 is a cytoskeletal protein involved in the dynamic regulation of synaptic NMDAR 
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complex formation that links the receptors to downstream signaling moieties (Delint-
Ramirez et al. 2008; Kurisaki et al. 2008). As shown in Figure 8A and Figure 8B, after 2 
days of moderate ethanol exposure, the levels of both NR2B-pY1472 (2B-pY1472) and 
PSD-95 were significantly elevated. Furthermore, although ethanol preconditioning 
potentiated NR2B protein levels at this time (Fig. 7 and Fig. 8A), tyrosine kinase activity 
acting on NR2B—most likely of the src family—was evidently increased as well, as 
demonstrated by the significantly increased ratio of NR2B-pY1472/total NR2B (pY/2B 
in Fig. 8B) in ethanol-treated cultures. The results point to NMDAR subunit upregulation 
in association with enhanced synaptic NMDAR localization as relatively early events of 
the ethanol preconditioning mechanism. 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
 
 
Figure 8: Increased synaptically-localized NMDAR Complex indicated by increases 
in NR2B phosphotyrosine-1472 PSD-95 and NR2B-pY1472/Total NR2B by Day 2 of 
MEP  
Cerebellar cultures (10DIV) were treated with 30mM ethanol (E) or control (C) media for 
48h, protein extracted and subjected to immunoblot analyses. A. Representative 
immunoblots of post-synaptic scaffolding protein PSD-95, NMDAR subunit NR2B 
phosphorylated tyrosine 1472 (2B-pY1472) and total NR2B. B. Immunoblot 
quantification of PSD-95, NR2B-pY1472 (normalized to actin) and the ratio of 2B-
pY1472 to total NR2B, expressed as % control. *p<0.05 vs. control by student t-test (n = 
3-6). 
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4.5.3 Discussion 
An exciting finding of NMDAR dynamics related to our ethanol preconditioning 
model is our evidence for early MEP-dependent receptor increases that reflect synaptic as 
opposed to extrasynaptic NMDAR. Specifically, levels of NR2B phospho-tyrosine 1472, 
which are associated with decreased endocytosis and synaptic enrichment of NMDAR 
(Yu et al. 1997; Goebel-Goody et al. 2009), and levels of PSD-95, which implicate 
increased synaptic receptor localization (Delint-Ramirez et al. 2008; Kurisaki et al. 
2008), are increased. These findings are in harmony with data showing that increases in 
synaptic NMDAR signaling are associated with downstream pro-survival events (Soriano 
et al. 2006; Soriano and Hardingham 2007). Furthermore, the significantly augmented 
ratio of NR2B-pY1772/total NR2B at an early MEP timepoint of 2 days indicates the 
possibility of increased activity of Src-family kinase(s) (Goebel-Goody et al. 2009). Src 
has only recently been demonstrated to be involved in ischemic and NMDA 
preconditioning of neurons (Head et al., 2008), although it has been reported in heart 
preconditioning. Therefore I wanted to examine if Src activation could explain the 
increases in NMDAR2B-Y1472 phosphorylation. Also, Pyk2 was investigated, since it is 
known to facilitate NMDAR activity. 
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4.6 Phosphoactivation of Src family and Pyk2 non-receptor tyrosine kinases by  
MEP 
 
4.6.1 Introduction 
MEP appears to be mediating an early recruitment of NMDAR to the PSD as 
described in Figure 8. Two non-receptor tyrosine kinases associated with the PSD are 
Pyk2 and Src. Both play an intimate role in the physiological role of excitatory 
neurotransmission (Lev et al., 1995). Pyk2 associates with and is trans-
autophosphorylated/activated directly by PSD-95 and has also been shown to be required 
for LTP (Bartos et al., 2010). Furthermore, Src (Ali and Salter, 2001) (Lu et al., 1998) 
and possibly Fyn (Nakazawa et al., 2001) have been shown to phosphorylate the NR2B 
subunit directly, preventing NMDAR endocytosis and enhancing synaptic localization. I 
explored the possibility that MEP was activating these synaptic signaling moieties, which 
may be associated with the early phosphorylation of NR2B phospho-tyrosine 1472 and 
upregulation of PSD-95. 
 
4.6.2 Results 
Figure 9A shows that at 48 h of MEP, there are significant elevations in the 
phospho-activated forms of pSrc and pPyk2 synaptic non-receptor tyrosine kinases. 
Figure 9B shows the quantification of these observations. The results provide further 
biochemical evidence that MEP increases the synaptic localization and the activity of 
signaling moieties associated with synaptic NMDA receptor complex. The novelty of 
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these observations may lie in their ability to transduce signals to multiple downstream 
targets and cross-talk with survival signals of the MAPK family. 
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Figure 9: Phosphoactivation of Src-family and Pyk2 non-receptor tyrosine kinases 
by 48 h of MEP, correlating with phosphorylation of NR2B tyrosine 1472 
A. Cerebellar cultures (10DIV) were treated with 30mM ethanol (E) or control (C) 
media. Protein was extracted and subjected to immunoblot analyses for anti-p-Src 
(Tyr416) and p-Pyk2 (Tyr402) at 48 h. Blots were then stripped and probed with 
corresponding non-phosphorylated antibodies. B. Quantification of A. Data represents 
%phospho/total. *p<0.05 (n= 3-4).  NOTE: anti-Fyn was used as loading control for p-
Src due to recognition of multiple p-Src family members. 
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4.6.3 Discussion 
 The phospho-activated form Src was elevated by 48 h of MEP a timepoint 
consistent with the observed increase in NR2B-pY1472. There seems to be some debate 
in the literature as to the exact Src-family member that is responsible for the NR2B-
Y1472 phosphorylation. However, the anti phospho Src-family antibody (recognizes Src-
family phospho-activation domain) employed in this study identified 3 bands that were 
elevated when compared to control, all of which are consistent with the hypothetical mol. 
wt. of at least Src and Fyn; and levels of total Fyn (used as loading control) did not differ. 
This implies that MEP is acting via Src-family kinases to increase NR2B-Y1472 
phosphorylation that is strongly correlated with synaptic receptor localization. 
Furthermore, this indicates that a degree of synaptic plasticity is occurring in these 
preconditioned cultures. 
Elevations in the phospho-activated form of Pyk2 further support data implicating 
increased synaptic NMDAR activity early in MEP’s neuroprotective mechanism. Pyk2, 
like Src, has been implicated in synaptic plasticity. This non-receptor tyrosine kinase is 
responsive to increases in intracellular calcium and interacts with MAPK pathways. 
Interestingly, a recent report sheds light on this mechanism, one that may well be 
involved in MEP. Pyk2 binds to PSD-95 in a calcium/calmodulin-dependent way (Bartos 
et al., 2010) providing the close proximity required for its trans-autophosphorylation of 
tyrosine 402. Phosphorylation of this site activates Pyk2 and provides a docking site for 
Src family kinases (binding via their SH2 domain to Pyk-pY402), which further 
phosphorylates and augments Pyk2 kinase activity. Src as previously mentioned is well 
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known to phospho-activate NMDAR and maintain them at the synapse. Thus it seems 
plausible that MEP enhances the synaptic NMDAR complex and may, speculatively, 
induce formation of a “postsynaptic signalosome” that acts as a “sensor” complex in 
MEP-dependent neuroprotection. 
 
4.7 Increased NMDAR2B and PSD-95 colocalization by MEP 
 
4.7.1 Introduction 
Biochemical data are highly indicative of a mechanism by which MEP increases 
synaptic NMDAR and subsequently the receptor’s ability to engender a neuroprotective 
phenotype. However, it should follow that there is a quantitative increase in synaptic 
localization of the NMDAR complex. In order to approach this issue, deconvolution 
microscopy was employed. This imaging technique in conjunction with Imaris, a 
program that assembles 3D images from deconvolved image z-planes, allows for the 
highly accurate quantification of fluorescent images in 3 dimensions. A Delta vision 
deconvolution microscope in the laboratory of Dr. Edward Campbell, Department of 
Microbiology and Immunology, LUMC, was utilized for all image acquisition. This 
microscope is equipped with a multi-filter (narrow band pass, excitation emission) wheel 
and allows for simultaneous allocation of images from multiple fluorescent channels. 
Thus, in order to ascertain whether there was an enhancement of NMDAR synaptic 
content in MEP vs. control cultures, I employed antibodies for βIII tubulin, as a neuronal 
marker, PSD-95, as a component of the postsynaptic density, and NR2 subunits 
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(panNR2), for visualization of the NMDAR complex. These antibodies were selected 
based on their optimal affinity to epitope for fluorescence microscopy.  
 
4.7.2 Results 
The experimental approach was to utilize this technique to identify post-synaptic 
densities via PSD-95 immunoreactivity and then quantify the amount of NMDAR 
complex (defined by NR2 intensities) within these postsynaptic densities. The logic 
behind this approach is that if there is an increase in the NMDAR imunofluorescence 
within the postsynaptic densities in MEP compared to control, than indeed MEP is 
increasing the synaptic content of the NMDAR complex. Control (Fig. 10, top panel) and 
MEP-treated neurons (Fig. 10, bottom panel) were identified by βIII tubulin 
immunoreactivity (column 1, Fig. 10). PSD-95 (column 2, Fig. 10) was blind at the time 
of image acquisition (the emission spectrum for Cy5, the fluorophore linked to the PSD-
95 secondary antibody, is invisible to the naked eye). An antibody that recognizes all 
NR2 subunits was employed for NMDAR visualization (Fig. 10, column 3). Column 4 of 
Figure 10 is a merged image of PSD-95 and NR2. Inlays under each representative image 
are an enlarged view of a neurite from the above channel. Shown in Figure 10, it appears 
that upon visual inspection that there is an enhancement of the NR2/PSD-95 
imunofluorescence; amount of yellow in comparing neurite to neurite. 
However, the power of this technique is the highly accurate quantification of 
images. Figure 11 depicts the quantification of these images. Image stacks were collected 
for both groups (blindly and in the same sitting) and deconvolved for later quantification. 
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An algorithm was constructed using Imaris by first selecting the PSD-95 channel (not 
visible at the time of data collection) and inclusion criteria set for PSD-95 
immunoreactive surfaces that were clearly visible to the naked eye. This same algorithm 
was then used to analyze all subsequent image stacks and retrospectively analyzed for 
statistical significance using either Systat or Graphpad prism. Figure 11A is a plot of the 
mean intensities of panNR2 vs. PSD-95 within the areas defined by PSD-95. Red dots in 
Figure 11A represent the control surfaces (defined by PSD-95 immunoreactivity and 
plotted as mean intensities of panNR2 vs. PSD-95, see Fig. 11D for clarity) and the blue 
diamonds represent the MEP-treated surfaces. This plot reveals a general tendency for 
increased NR2 intensities within the PSDs for the MEP treated vs. control cultures. 
Figure 11B is a graphical representation of the data in Figure 11A for the NR2 intensities 
within the PSD. Figure 11C is the mean PSD fluorescence for control and MEP within 
the PSDs. Figure 11D is a pictorial view of the surfaces identified by PSD-95 (red) and 
NR2 (green) within these surfaces. It is evident from theses data that MEP increases the 
synaptic NMDAR complex and increases the PSD-95 intensities after 6 days of MEP. 
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Figure 10: Increased colocalization of PSD-95 and NR2 subunits by MEP 
Representative images of cerebellar cultures (10DIV) treated with control (upper panel) 
or 30mM ethanol (MEP, lower panel) media for 6 days. Cultures were fixed and stained 
with the appropriate antibodies (chicken α-βIII Tubulin 1:500, mouse α-PSD-95 1:200 
and rabbit α-pan NR2 1:500), rinsed 3X and stained with the appropriate 2’ antibody 
(Cy2 conjugated  α-rabbit, Cy3 α-chicken and Cy5 α-mouse; all goat & 1:400). Images 
were collected on a Delta Vision deconvolution microscope (60X objective) and a 
representative z-plain is shown. Inset below each channel is an enlarged view of a neurite 
from the image above. Image stacks were cropped and channel colors chosen using the 
MacBiophotonics ImageJ bundle. Intensities for individual channels are constant between 
groups. Scale bar = 5µm. 
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Figure 11: Quantification of PSD-95 and NR2 intensities following MEP 
Cerebellar cultures (10DIV) were treated with control or 30mM ethanol (MEP) media for 
6 days, fixed and stained with the appropriate antibodies. Image stacks were collected 
with a Delta Vision deconvolution microscope (60X objective) and analyzed with Imaris 
6.3.1. 3D surfaces were defined by PSD-95 punctum and analyzed for PSD-95 and pan 
NR2 mean intensity per surface. A. Plot of Mean NR2 Vs. mean PSD-95 intensities; red 
square = Control and blue diamond = MEP. B. Mean NR2 intensities for surfaces defined 
by PSD-95. C. Mean PSD-95 intensities. D. Representative 3D image generated with 
Imaris 3.1 showing PSD-95 (red) and pan NR2 (green). Gray surfaces represent areas 
quantified. At least 20 neurons were imaged per group. *p<0.0001. 
 
 
 
 
 
 
 
93 
 
 
 
D
 
 
 
 
94 
 
 
 
4.7.3 Discussion 
It is interesting that as early as two days there are increases in PSD-95 and 
NR2BpY1472, which may indicate a strengthening of the NMDAR synaptic content of 
the cultures early in the preconditioning paradigm. What is potentially more striking is 
that the co-localization as defined by deconvolution microscopy is also apparent at day 6 
of MEP when neuroprotection is evident. Together with the data indicating increases in 
pPyk2 and pSrc at the 2 day timepoint, the data seem to be consistent with MEP initiating 
plasticity at an early time that results in a persistent increase in the NMDAR content of 
postsynaptic densities. This has several possible implications for the mechanism of MEP 
and quite possibly modalities of brain preconditioning in general. 
My biochemical data indicate a strengthening of the synaptic NMDAR complex 
in MEP’s neuroprotective mechanism, and this agrees well with the growing literature on 
the neuroprotective role of synaptic NMDAR activity. However, it should follow that 
there is a physical increase in the synaptic NMDAR content, and in fact, deconvolution 
microscopy revealed an increase in the colocalization of NR2 (pan-NR2 antibody) and 
PSD-95 following the 6 day MEP protocol. When PSD-95 puncta were identified using 
the quantification software Imaris, MEP-treated cultures had a significantly elevated 
mean NR2 intensity compared to control. Thus it appears that an early activation of the 
non-receptor tyrosine kinases, Src and Pyk2, and a concomitant increase in the expression 
of PSD-95 and NMDAR subunits results in an increase in the synaptic NMDAR complex 
in preconditioned cultures. Furthermore, these changes are consistent with those reported 
during synaptic plasticity in vivo, since early tyrosine kinase and NR2B phosphorylation 
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also result in a sustained increase in the synaptic NMDAR complex. Thus at least in 
vitro, MEP appears to cause plasticity responses that elicit a neuroprotective phenotype in 
response to amyloid challenge. 
 
4.8 NMDAR-dependent antioxidant system enhanced by moderate ethanol 
preconditioning 
 
4.8.1 Introduction 
Data thus far have been consistent with a mechanism involving recruitment and 
strengthening of the NMDAR synaptic complex. Recently, Papadia and coworkers 
reported in an elegant study isolating synaptic NMDAR that synaptic NMDAR activity 
enhanced a neuron’s intrinsic antioxidant defenses via the peroxyredoxin thioredoxin 
pathway (Papadia et al., 2008). Given that Aβ toxicity involves excessive ROS and that 
synaptic NMDAR content is enhanced in MEP-treated compared to control cerebellar 
mixed cultures, this study provides a novel effector mechanism to help explain the 
neuroprotected phenotype. If MEP is enhancing the neuron’s pro-survival capacity via 
the synaptic NMDAR complex, then it may be upregulating the peroxyredoxin 
thioredoxin pathway, thereby reducing Aβ neurotoxicity. Speculatively, the upregulation 
of antioxidant enzymes due to NMDAR activity (or other routes of synaptic calcium 
entry) may predispose a neuron receiving excitatory synaptic input through NMDAR to 
have resistance to oxidative stress (calcium entry is a known source of ROS), even from 
pathological insults.  
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4.8.2 Results 
In order to explore this possibility, I investigated the relationship between MEP 
and the small molecular weight antioxidant peroxiredoxins. Although this work is 
preliminary at this juncture, the initial results show strong evidence that the 2-Cys 
peroxyredoxin2, a cytosolic member of this protein family, is increased at day 6 of MEP, 
consistent with a time point when neuroprotection is evident (Fig. 12). Furthermore, 
memantine co-treatment blocks this induction, consistent with MEP enhancing NMDAR 
signaling and causing the upregulation of this pathway. However, more work needs to be 
done, since the other enzymes in this pathway, mainly thioredoxin and thioredoxin 
reductase, are seemingly equally as important for antioxidant defenses. 
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Figure 12: Increased expression of peroxiredoxin II by MEP and reversal by 
memantine 
 Cerebellar cultures (10DIV) were treated with 30mM ethanol (E) or control (C) media 
for 2 and 6 days (w./w.o. memantine), protein extracted and subjected to immunoblot 
analyses. Extracts were probed with an antibody for pan 2 cys-peroxiredoxin and bands 
were identified by their theoretical Mol. Wt. Lane 1 is an equal concentration of protein 
lysate from rat brain cerebella at postnatal day 8.  A non-specific (NS) band of ~100kD is 
shown for loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
 
 
4.8.3 Discussion 
Figure 12 provides evidence that imply the NMDAR changes observed in 
response to MEP are initiating the neuroprotective phenotype by increases in prx2. This 
is a cytosolic antioxidant observed primarily in neurons. Augmentation of this pathway 
has been linked to increased synaptic NMDAR activity (Papadia et al. 2008). The 
preliminary experiments showed increases in this enzyme at day 6 of MEP, but not 
earlier. Importantly, memantine co-treatment, which blocks NR1 expression and MEP 
neuroprotection, also blocked the increased expression of prx2, indicating that prx2 may 
be a previously unappreciated NMDAR-dependent “effector” in this preconditioning 
paradigm.  
Another interesting point regarding prx2 is that it is increased in AD brain. This 
may indicate a natural process during AD progression which upregulates this antioxidant 
enzyme, presumably in an attempt to protect neurons from accumulating amyloid burden 
(Yao et al., 2007). Further, this publication shows that transfection with prx2 is sufficient 
to block Aβ neurotoxicity. An aspect of this paper that was not addressed is that their 
control transfection was PSD-95, which provided no protection from Aβ. It has been 
shown that PSD-95 alone is capable of clustering NMDAR complex, but the relatively 
short post-transfection timeframe (72 hour, additionally these mouse cortical neurons 
were transfected at plating and only allowed to develop for 72 h prior to Aβ exposure) 
may be such that it was unable to produce the increase in NMDAR activity and so 
increase the expression of prx2 (biochemical data showing expression of prx2 were not 
supplied for transfection experiments). The relationship between NMDAR synaptic 
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activity and this antioxidant system (Papadia et al. 2008) was, to my knowledge, not 
known at the time of this publication. It is conceivable that the increase in prx2 observed 
in vitro with MEP could occur in vivo. Such an early increase in prx2 may occlude the 
increased expression of prx2 in response to elevated amyloid peptides during AD 
progression, thereby preserving neuronal function. 
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CHAPTER FIVE  
OVERALL DISCUSSION AND SIGNIFICANCE 
 
One overall conclusion derived from these experiments is that neuroprotection 
engendered by preconditioning rat cerebellar cultures with moderate ethanol 
concentrations involves NMDAR activation as a likely neuroprotective sensor.  
Pharmacological inhibition of NMDAR early during MEP disallows later 
neuroprotection. In contrast, antagonism of adenosine A1 receptors or of Gαi/o protein-
coupled receptors is without effect (Fig. 5). The data agree with preconditioning results 
demonstrating NMDAR involvement in ischemic preconditioning published soon after 
the discovery of ischemic neuronal tolerance (Kato et al. 1992). More recent reports 
further confirm a neuroprotective role for NMDAR in ischemic preconditioning (Grabb 
and Choi 1999; Raval et al. 2003).  
The fact that preconditioning cerebellar cultures with subneurotoxic NMDA 
ligand itself affords neuroprotection from Aβ (Fig. 6) strengthens the idea that NMDAR 
activation is capable of mediating moderate ethanol-initiated prosurvival signaling. This 
is consistent with NMDA preconditioning/neuroprotection results using other primary 
cultures (Soriano et al. 2006; Smith et al. 2008). NMDAR excitability also appears 
critical in preconditioning with glutamate or prolonged elevations in electrical activity, 
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since NMDAR antagonists block the resultant neuroprotection against subsequent 
ischemia (Lin et al. 2008; Tauskela et al. 2008). However, despite these findings, itshould 
be acknowledged that NMDA’s protective mechanism and ethanol’s mechanism of 
neuroprotection may differ in other ways. 
 Ethanol is known to acutely inhibit and chronically potentiate NMDAR currents, 
although exact mechanisms remain a matter of intense investigation (Nagy 2008). 
Persistent increases in subunits NR1, NR2B and NR2C occur by the first 2 days of 
moderate ethanol exposure and persist through day 6 (Fig. 7). Such increases in receptor 
subunits could be a principal reason for increased NMDAR activity leading to 
neuroprotection, as shown in Figure 13A. This possibility is supported by the finding that 
memantine blocked the ethanol-dependent increases in NR1, the receptor’s obligatory 
subunit—thus lessening NMDAR activity—concurrent with abolishing MEP 
neuroprotection. Of relevance to these in vitro findings are in vivo studies demonstrating 
improved NR1-dependent memory performance in rats chronically fed moderate ethanol-
containing diets (Kalev-Zylinska and During 2007). RNA interference knockdown of 
hippocampal NR1 abolished ethanol’s facilitatory effects on cognition, while NR1 
overexpression mimicked ethanol’s effects. Thus, although NR2 subunits are known 
ethanol targets (Woodward et al. 2006), changes in NR1 subunits often appear critical for 
NMDAR function. 
A further critical aspect of MEP is our evidence for early NMDAR subunit 
increases that indicate the involvement of synaptic as opposed to extrasynaptic NMDAR. 
Specifically, MEP elevates levels of NR2B phospho-tyrosine 1472 , which are associated 
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with synaptic enrichment of NMDAR and decreased NMDAR endocytosis (Yu et al. 
1997; Goebel-Goody et al. 2009), and levels of PSD-95, which implicate increased 
synaptic receptor localization (Delint-Ramirez et al. 2008; Kurisaki et al. 2008), as 
represented in Figure 13. These findings are in harmony with data showing that increases 
in synaptic relative to extrasynaptic NMDAR signaling are associated with downstream 
pro-survival events (Soriano et al. 2006; Soriano and Hardingham 2007).  
Furthermore, the significantly augmented ratio of NR2B-pY1772/total NR2B at 
an early MEP timepoint of 2 days indicates increased activity of Src-family kinase(s) 
(Goebel-Goody et al. 2009). This possibility was confirmed, since the phospho-activated 
form of Src (Fig. 9) was elevated by 48 h of MEP, a timepoint consistent with the 
observed increase in NR2B-pY1472. There is debate in the literature as to the exact Src-
family member that is responsible for the NR2B-Y1472 phosphorylation. However, the 
antiphospho-Src-family antibody (recognizes Src-family phospho-activation domain) 
employed in this study identified 3 bands that were elevated when compared to control, 
all of which are consistent with the hypothetical mol. wt. of at least Src and Fyn (Fig. 8); 
levels of total Fyn (used as loading control) did not differ. This implies that MEP is 
acting via Src-family kinases to increase NR2B-Y1472 phosphorylation. Since this 
NR2B-Y1472 phosphorylation correlates with synaptic receptor localization, the finding 
suggests that a significant amount of synaptic plasticity is occurring in these 
preconditioned cultures. 
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Figure 13: Hypothetical model for the involvement of the NMDAR complex in MEP 
neuroprotection against Aβ neurotoxicity 
Ethanol preconditioning requires NMDAR activity early in its neuroprotective 
mechanism. NMDA preconditioning is capable of inducing neuroprotection from Aβ, 
lending additional support to the involvement of the NMDAR receptor in MEP-mediated 
neuroprotection. A. MEP increases expression of NMDAR subunits, phosphorylation of 
NR2B-Y1472 and postsynaptic scaffolding protein PSD-95 by day 2. Pyk2 and Src are 
also phospho-activated by day 2 of MEP treatment, a timepoint when elevations in these 
proteins are evident and NR2B-pY1472 is increased. B. By day 6 of MEP, a timepoint 
when MEP-dependent neuroprotection is evident, microscopy data show an increase 
colocalization of NR2 and PSD-95, as well as increased expression of the antioxidant 
enzyme prx2. Therefore, MEP causes recruitment of the NMDAR complex to the 
postsynaptic density within the neuron. This mechanism provides two potential 
explanations for MEP’s ability to protect from Aβ-neurotoxicity: 1) MEP increases 
NMDAR-dependent prosurvival signaling in general such as CREB activation and 
antioxidant defenses and 2) MEP shifts the pool of available receptor from the 
extrasynaptic or excitotoxic receptor to synaptic sites, increasing receptor efficacy in the 
face of amyloid burden and producing an environment less susceptible to amyloid 
neurotoxicity. 
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Another finding that correlates well with increased synaptic NMDAR activity 
early in MEP’s neuroprotective mechanism is the elevations in the phospho-activated 
form of Pyk2 (Fig. 8). Pyk2, like Src, has been implicated in synaptic plasticity. This 
non-receptor tyrosine kinase, which is responsive to increases in intracellular calcium, 
interacts with MAPK pathways. Interestingly, a very recent report found that Pyk2 binds 
to PSD-95 in a calcium/calmodulin-dependent manner (Bartos et al., 2010). This provides 
the close proximity required for its trans-autophosphorylation and activation of tyrosine 
402. Phosphorylation of this site activates Pyk2 and provides a docking site for Src 
family kinases (binding via their SH2 domain to Pyk-pY402), which further 
phosphorylate and augment Pyk2 kinase activity. Src, as previously mentioned, is well 
known to phospho-activate NMDAR at the synapse. Thus it seems plausible that MEP 
enhances the synaptic NMDAR complex and may, speculatively, induce formation of a 
“postsynaptic signalosome” complex in MEP’s neuroprotection (Collins et al., 2009, see 
Fig. 13). 
My biochemical data are strongly indicative of a strengthening of the synaptic 
NMDAR complex in MEP’s neuroprotective mechanism. This agrees with a growing 
literature on the neuroprotective role of synaptic NMDAR activity. However, it should 
follow that there is a physical increase in the synaptic NMDAR content. Indeed, 
deconvolution microscopy revealed an increase in the colocalization of NR2 (pan-NR2 
antibody) and PSD-95 following the 6 day MEP protocol (Fig. 10). When PSD-95 puncta 
were identified using the quantification software Imaris, MEP-treated cultures had a 
significantly elevated mean NR2 intensity vs. control (Fig. 11). Therefore, an early 
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activation of the non-receptor tyrosine kinases Src and Pyk2 and a concomitant increase 
in the expression of PSD-95 and NMDAR subunits (Fig. 13A) result in an increase in the 
synaptic NMDAR complex in preconditioned compared with control cultures (Fig. 13B). 
These changes are consistent with those reported during synaptic plasticity in vivo, since 
early tyrosine kinase and NR2B phosphorylation results in sustained increases in the 
synaptic NMDAR complex. Thus at least in vitro, MEP appears to be causing plasticity 
responses that elicit a neuroprotective phenotype. 
A final line of evidence that the NMDAR changes observed in response to MEP 
are initiating the neuroprotective phenotype is the increases in prx2 (Fig. 12). This 
cytosolic antioxidant is observed primarily in neurons. The peroxiredoxin-thioredoxin 
pathway has also been linked to synaptic NMDAR activity (Papadia et al., 2008). I 
observed increases in this enzyme at day 6 of MEP but not earlier. Importantly, 
memantine co-treatment, which blocks NR1 expression and MEP neuroprotection, also 
suppressed the increased expression of prx2 (Fig. 12). As depicted in Figure 13, this 
implicates prx2 as a previously unrecognized NMDAR-dependent “effector” in MEP. 
Another interesting point regarding this particular enzyme is that it is increased in AD 
brain, suggesting that there is a natural process during AD progression by which this 
antioxidant enzyme is increased, possibly to protect neurons from the accumulating 
amyloid burden (Yao et al., 2007). 
The authors further show that transfection with prx2 is sufficient to block Aβ 
neurotoxicity. However, their control transfection was PSD-95, which provided no 
protection from Aβ. It has been shown that PSD-95 alone is capable of clustering 
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NMDAR complex, but the relatively short post-transfection timeframe (72 hour, 
additionally these mouse cortical neurons were transfected at plating and only allowed to 
develop for 72h prior to Aβ exposure) may be such that it was unable to produce the 
increase in NMDAR activity and so increase the expression of prx2 (biochemical data 
showing expression of prx2 were not supplied for transfection experiment). It was not 
known at the time of the Yas publication the relationship between NMDAR synaptic 
activity and this antioxidant system  (Papadia et al., 2008). It is conceivable that the 
increase in prx2 observed in vitro with MEP occurs in vivo and there is some evidence for 
this possibility (Botia et al., 2008). Such an early increase in prx2 may supersede the 
expression in response to elevating amyloid peptides, preserving neuronal function in 
response to soluble amyloid burden during AD progression. 
Although growing evidence suggests a physiological function of amyloid peptide 
fragments pertaining to regulation of synaptic transmission and homeostasis (Pearson and 
Peers 2006), aberrant Aβ peptide overproduction is considered central to AD 
pathophysiology and possibly age-related mild cognitive decline. This concept is 
evidenced by the facts that synaptic loss correlates well with cognitive decline in vivo 
(Terry et al. 1991) and that Aβ peptides experimentally induce alterations in synapse 
composition and density (Lacor et al. 2007). AD is reaching epidemic proportions among 
aging populations (Wang and Ding 2008) and effective pharmaceutical approaches to 
slow AD progression are lacking. Investigations into the molecular mechanisms of 
ethanol preconditioning may help to clarify roles of NMDAR in AD etiology and offer 
new strategies for halting synaptic degeneration while preserving synaptic connectivity. 
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A recent report showed that Aβ-containing monomeric and oligomeric peptides 
bind to postsynaptic NMDAR-containing synapses, inhibit NMDAR, and decrease 
NMDAR immunoreactive spines and surface expression of NR2B-containing NMDAR 
(Dewachter et al. 2009). The authors also found decreased concentrations of NR2B and 
PSD-95 in a transgenic mouse model of AD. Others have reported that the suppressive 
effects of Aβ on NMDAR surface expression correlate with decreased NR2B-pY1472 
(Snyder et al. 2005). Our results indicate that ethanol preconditioning might combat 
neurodegenerative processes induced by Aβ and other neurotoxic proteins (e.g., HIV-1 
gp120) by preserving NMDAR-associated synaptic density and connectivity. MEP-
mediated neuroprotection seems to entail the ability of synaptically-localized NMDAR to 
enhance intrinsic antioxidant defenses—specifically, via peroxyredoxin and thioredoxin 
pathways. In view of considerable evidence that AD is characterized by excessive 
oxidative stress (Sultana et al. 2009), such a mechanism seems plausible. 
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CHAPTER SIX 
CONCLUDING REMARKS 
Brain preconditioning by multiple stimuli have shown the NMDAR to be an 
important sensor for preconditioning and as such, the results in this study are consistent 
with those published results. However, emerging evidence seems to implicate the 
specificity of synaptic responses as opposed to total activity in attaining NMDAR-
dependent neuroprotection. NMDAR synaptic activity has been linked to CREB 
activation and its downstream prosurvival signaling. Importantly, Aβ inhibits NMDA-
stimulated CREB activation (Snyder et al., 2005). Since CREB seems to play a critical 
role in preconditioning, CREB signaling should be investigated in MEP’s neuroprotective 
mechanism.  
Another interesting point is that amyloid peptides have been postulated to act as 
gain-of-function molecules for the NMDAR. Ethanol even in moderation can upregulate 
the NMDAR in vitro and in vivo. Thus, one might expect that Aβ would enhance 
excitotoxicity in ethanol-treated cultures. My results show MEP-induced upregulation of 
NMDAR at a timepoint that correlates with neuroprotection from Aβ. Furthermore, there 
is growing evidence that Aβ acts as an inhibitor of the NMDAR (Dewachter et al., 2007; 
Puzzo et al., 2008) and mediates excitotoxic calcium entry through α-7 nicotinic 
acetylcholine receptors (Snyder et al., 2005). This may partially explain why memantine, 
which has affinity for the α-7 receptor similar to that of the NMDAR 
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(Aracava et al., 2005), is the only NMDAR inhibitor that has been approved by the FDA 
for treatment of AD. Nevertheless, there is an obvious discrepancy in the literature on the 
mechanisms of AD pathology that demands further exploration.  
This work has identified the NMDAR as a probable sensor of MEP-
neuroprotection, as has been documented for other forms of preconditioning-induced 
neuroprotection. However, MEP seems to act via a distinct, novel and until now 
undescribed mechanism. That is, MEP increases the NMDAR content of the postsynaptic 
density. MEP, potentially by shifting the NMDAR pool from extra-synaptic (not 
associated with the PSD) to synaptic (associated with the PSD) surfaces, modulates the 
membrane content of the receptor to a more prosurvival, anti-excitotoxic phenotype, 
essentially providing less opportunity for extra-synaptic noise while inducing a higher 
propensity for legitimate synaptic transmission. This phenotype may also prime the 
neuron to accommodate a greater oxidant stress, as it has been primed to deal with the 
oxidant load by enhanced endogenous antioxidants.  
Furthermore, this same phenotype could be rendering neurons resistant to the 
elevated glutamate that has been reported in AD brains. Amyloid peptides seem to have 
important physiological functions in normal neuronal transmission and this point must be 
considered when designing logical therapeutic approaches to treating AD. With this in 
mind, it seems that MEP may be inducing an extracellular environment that is resistant to 
the actions of Aβ, and in so doing, thwart off the progression of AD or possibly induce a 
more regulated control of the amyloidogenic processes. Designing drugs that encapsulate 
these properties, but lack the undesirable effects of alcohol (such as the propensity for 
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abuse), would be a novel approach to treating both the neurodegenerative processes and 
the cognitive deficits associated with the AD. 
It would appear that amyloid peptides have both physiological roles and in excess 
pathological roles. Memantine is the only FDA-approved drug for the treatment of 
moderate to severe AD. Memantine has been reported to act by enhancing the efficacy of 
synaptic transmission, inhibiting the pathological activation of extrasynaptic NMDARs 
while preserving the physiological function of the receptor in normal synaptic 
(depolarized, voltage-sensitive) transmission (Leveille et al., 2008). Ethanol 
preconditioning, or by extension, moderate alcohol consumption, found in some studies 
to be protective against dementia in older individuals, may be working similar to 
memantine—but potentially by a different mechanism, by trafficking the receptor from 
the extrasynaptic to synaptic regions, thereby increasing the efficacy of synaptic 
(prosurvival) events what while decreasing the pathological extrasynaptic excitotoxicity. 
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